masran的个人主页 - 老虎社区

masran

masran

暂无个人介绍

IP属地：未知

261关注

16粉丝

0主题

0勋章

2021-12-24

thx

抱歉，原内容已删除

2021-12-24

pls like

抱歉，原内容已删除

2021-12-24

good to hear

抱歉，原内容已删除

2021-12-23

like pls

抱歉，原内容已删除

2021-12-21

thx

Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>

2021-12-20

NIO very impressive

抱歉，原内容已删除

2021-12-18

like pls

抱歉，原内容已删除

2021-12-17

let see

抱歉，原内容已删除

2021-12-17

hurray

Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>

2021-12-16

thx

抱歉，原内容已删除

2021-12-16

good thought

Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>Cathie Wood 在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了 8800 万美元</blockquote>

2021-12-16

hurray

Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>

2021-12-16

need booster

Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>

2021-12-10

wow

Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘交易中下跌</blockquote>

2021-12-10

like pls

Grab and Lucid stocks plunged more than 10%<blockquote>Grab 和 Lucid 股价暴跌超过 10%</blockquote>

2021-12-02

coming up soon

Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价上涨至下跌4%</blockquote>

2021-11-30

good

Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>

2021-11-30

think again

抱歉，原内容已删除

2021-11-30

enjoy wen it go up

AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票 NFT 赠品的 AMC 股票趋势</blockquote>

2021-11-24

enjoy the holiday

Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：美国股市将于周四感恩节休市，周五提前三小时休市</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582888796077977","uuid":"3582888796077977","gmtCreate":1619796055209,"gmtModify":1630548061864,"name":"masran","pinyin":"masran","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":16,"headSize":261,"tweetSize":98,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698851498,"gmtCreate":1640347839561,"gmtModify":1640347839791,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698851498","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":3349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":4185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698965862,"gmtCreate":1640278323261,"gmtModify":1640278323493,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"good to hear","listText":"good to hear","text":"good to hear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698965862","repostId":"1192606453","repostType":2,"isVote":1,"tweetType":1,"viewCount":3330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691250012,"gmtCreate":1640213796164,"gmtModify":1640213796381,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691250012","repostId":"1131862374","repostType":4,"isVote":1,"tweetType":1,"viewCount":3488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"repost":{"id":"1149530831","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640078220,"share":"https://www.laohunote.com/m/news/1149530831?lang=zh_CN&edition=full","pubTime":"2021-12-21 17:17","market":"us","language":"en","title":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149530831","media":"Tiger Newspress","summary":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Ma","content":"<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会 (EC) 已批准 Veklury 有条件营销授权的变更®（瑞德西韦）包括不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）的科学委员会人用药品委员会（CHMP）于12月16日提出扩大Veklury适应症的积极建议之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着 COVID-19 的发病率再次攀升以及奥密克戎等新变种的出现，我们需要像 Veklury 这样的有效工具来治疗该疾病的各个阶段，”IrsiCaixa 艾滋病研究所 Hospital Universitari Germans Trias I Pujol Badalona，西班牙。“我们现在可以使用 Veklury 来帮助防止高危患者发展为更严重的疾病，即使他们不需要氧气，并继续使用 Veklury 作为治疗严重疾病的关键工具。这项最新的批准也将有助于缓解医疗保健系统的一些压力，这些系统已经因 COVID-19 的负担而承受着巨大的压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>欧盟委员会的决定得到了一项 3 期随机、双盲、安慰剂对照试验结果的支持，该试验评估了在疾病进展高风险的非住院患者中静脉注射 (IV) 三天 Veklury 治疗 COVID-19 的疗效和安全性。在对以1:1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，Veklury显示，与安慰剂（5.3%【15/283】）相比，第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗紧急不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症补充了之前Veklury的有条件营销授权，使其能够治疗患有肺炎的成人和青少年（12至18岁以下，体重至少40 kg）的新冠肺炎，这些肺炎需要补充氧气（低流量或高流量氧气或治疗开始时的其他非侵入性通气）。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官 Merdad Parsey 医学博士表示：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些治疗方法可以在疾病过程的早期使用，以帮助整个欧洲的 COVID-19 患者。”“随着我们对 COVID-19 疾病如何进展的了解越来越多，很明显，如果在疾病过程的早期使用，像 Veklury 这样的抗病毒药物可以产生重大影响。作为 COVID-19 住院患者的抗病毒护理标准，我们为 Veklury 继续在大流行前线发挥的作用感到自豪，我们相信 Veklury 现在将能够帮助欧洲更多患者缩短从 COVID-19 中康复的时间。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会 (EC) 已批准 Veklury 有条件营销授权的变更®（瑞德西韦）包括不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）的科学委员会人用药品委员会（CHMP）于12月16日提出扩大Veklury适应症的积极建议之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着 COVID-19 的发病率再次攀升以及奥密克戎等新变种的出现，我们需要像 Veklury 这样的有效工具来治疗该疾病的各个阶段，”IrsiCaixa 艾滋病研究所 Hospital Universitari Germans Trias I Pujol Badalona，西班牙。“我们现在可以使用 Veklury 来帮助防止高危患者发展为更严重的疾病，即使他们不需要氧气，并继续使用 Veklury 作为治疗严重疾病的关键工具。这项最新的批准也将有助于缓解医疗保健系统的一些压力，这些系统已经因 COVID-19 的负担而承受着巨大的压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>欧盟委员会的决定得到了一项 3 期随机、双盲、安慰剂对照试验结果的支持，该试验评估了在疾病进展高风险的非住院患者中静脉注射 (IV) 三天 Veklury 治疗 COVID-19 的疗效和安全性。在对以1:1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，Veklury显示，与安慰剂（5.3%【15/283】）相比，第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗紧急不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症补充了之前Veklury的有条件营销授权，使其能够治疗患有肺炎的成人和青少年（12至18岁以下，体重至少40 kg）的新冠肺炎，这些肺炎需要补充氧气（低流量或高流量氧气或治疗开始时的其他非侵入性通气）。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官 Merdad Parsey 医学博士表示：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些治疗方法可以在疾病过程的早期使用，以帮助整个欧洲的 COVID-19 患者。”“随着我们对 COVID-19 疾病如何进展的了解越来越多，很明显，如果在疾病过程的早期使用，像 Veklury 这样的抗病毒药物可以产生重大影响。作为 COVID-19 住院患者的抗病毒护理标准，我们为 Veklury 继续在大流行前线发挥的作用感到自豪，我们相信 Veklury 现在将能够帮助欧洲更多患者缩短从 COVID-19 中康复的时间。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149530831","content_text":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.\n\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"\nThe EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.\nThis expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).\n\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":2946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693692245,"gmtCreate":1640011205087,"gmtModify":1640011205299,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"NIO very impressive","listText":"NIO very impressive","text":"NIO very impressive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693692245","repostId":"1164238522","repostType":2,"isVote":1,"tweetType":1,"viewCount":2693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"isVote":1,"tweetType":1,"viewCount":2832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690583165,"gmtCreate":1639691863789,"gmtModify":1639691863955,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"let see","listText":"let see","text":"let see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690583165","repostId":"2191674549","repostType":2,"isVote":1,"tweetType":1,"viewCount":2927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690589177,"gmtCreate":1639691736246,"gmtModify":1639691849682,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690589177","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","kind":"news","pubTimestamp":1639620135,"share":"https://www.laohunote.com/m/news/1117904160?lang=zh_CN&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（NYSE:NIO）日即将到来，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-16 10:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（NYSE:NIO）日即将到来，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":2800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334260,"gmtCreate":1639632309401,"gmtModify":1639632440388,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334260","repostId":"2191099021","repostType":2,"isVote":1,"tweetType":1,"viewCount":3616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690334652,"gmtCreate":1639632284485,"gmtModify":1639632416387,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"good thought","listText":"good thought","text":"good thought","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690334652","repostId":"1191022113","repostType":2,"repost":{"id":"1191022113","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639626011,"share":"https://www.laohunote.com/m/news/1191022113?lang=zh_CN&edition=full","pubTime":"2021-12-16 11:40","market":"us","language":"en","title":"Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>Cathie Wood 在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了 8800 万美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191022113","media":"Benzinga Earnings","summary":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — i","content":"<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了 90,455 股股票，估计价值 8,830 万美元<b>特斯拉公司</b>该股在连续几天亏损后上涨，因此记录了利润。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收盘上涨 1.82%，至每股 975.99 美元，收盘上涨 1.82%。埃隆-马斯克（Elon Musk）领导的这家公司的股价今年迄今已上涨约 34%，过去一个月下跌约 7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest 通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>方舟自主技术与机器人 ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易前，特斯拉在 ARKK 和 ARKW 的权重已经跌破 10% 的门槛，分别为 8.14% 和 9.35%。在 ARKQ，它占投资组合的 10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易前，这三只 ETF 在特斯拉持有 199 万股股票，价值 19.1 亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest 自 9 月份以来一直在特斯拉实现盈利，出售了价值超过 30 亿美元的股票，此前该公司多年来一直在低得多的水平囤积这家电动汽车公司的股票。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在 ETF 中最大的赌注——该公司预测该股到 2025 年底将突破 3,000 美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他主要交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了 104,489 股股票，估计价值 2,130 万美元<b>Roku公司</b>在蘸酱上。该股周三收盘下跌 7.95%，至每股 203.94 美元。</li><li>购买了 705,660 股股票，估计价值 1,370 万美元<b>罗宾汉市场公司</b>该股收盘上涨 1.93%，至每股 19.50 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>Cathie Wood 在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了 8800 万美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Sells Another $88M In Tesla Day After Piling Up Stake In Chinese EV Rival<blockquote>Cathie Wood 在增持中国电动汽车竞争对手股份后，在特斯拉日又出售了 8800 万美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-16 11:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Cathie Wood</b>-led&nbsp;<b>Ark Invest</b>&nbsp;on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in&nbsp;<b>Tesla Inc</b>, booking profit in the stock as it rose after days of losses.</p><p><blockquote><b>凯西·伍德</b>-led<b>方舟投资</b>周三出售了 90,455 股股票，估计价值 8,830 万美元<b>特斯拉公司</b>该股在连续几天亏损后上涨，因此记录了利润。</blockquote></p><p> The stock pared earlier losses to close&nbsp;1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.</p><p><blockquote>该股周三收盘上涨 1.82%，至每股 975.99 美元，收盘上涨 1.82%。埃隆-马斯克（Elon Musk）领导的这家公司的股价今年迄今已上涨约 34%，过去一个月下跌约 7.5%。</blockquote></p><p> Ark Invest sold the shares via the&nbsp;<b>Ark Innovation ETF</b>(BATS:ARKK), the&nbsp;<b>Ark Autonomous Technology &amp; Robotics ETF</b>(BATS:ARKQ) and the&nbsp;<b>Ark Next Generation Internet ETF</b>(BATS:ARKW)&nbsp;on Wednesday.</p><p><blockquote>Ark Invest 通过<b>方舟创新ETF</b>（蝙蝠：ARKK），<b>方舟自主技术与机器人 ETF</b>（蝙蝠：ARKQ）和<b>方舟下一代互联网ETF</b>（蝙蝠：ARKW）周三。</blockquote></p><p> Tesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.</p><p><blockquote>在周三交易前，特斯拉在 ARKK 和 ARKW 的权重已经跌破 10% 的门槛，分别为 8.14% 和 9.35%。在 ARKQ，它占投资组合的 10.59%。</blockquote></p><p> The three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.</p><p><blockquote>在周三交易前，这三只 ETF 在特斯拉持有 199 万股股票，价值 19.1 亿美元。</blockquote></p><p> Ark Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.</p><p><blockquote>Ark Invest 自 9 月份以来一直在特斯拉实现盈利，出售了价值超过 30 亿美元的股票，此前该公司多年来一直在低得多的水平囤积这家电动汽车公司的股票。</blockquote></p><p> Tesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the&nbsp;$3,000 mark by the end of 2025.</p><p><blockquote>特斯拉仍然是该公司在 ETF 中最大的赌注——该公司预测该股到 2025 年底将突破 3,000 美元大关。</blockquote></p><p> Wood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker&nbsp;<b>Xpeng Inc</b>.</p><p><blockquote>伍德支持汽车行业转向电动汽车，并于本月早些时候开始购买这家在美国上市的中国电动汽车制造商的股票<b>小鹏汽车</b>.</blockquote></p><p> Here are the other key trades on Wednesday:</p><p><blockquote>以下是周三的其他主要交易：</blockquote></p><p> <ul>  <li>Bought 104,489 shares — estimated to be worth $21.3 million — in&nbsp;<b>Roku Inc</b>&nbsp;on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.</li>  <li>Bought 705,660 shares — estimated to be worth $13.7 million — in&nbsp;<b>Robinhood Markets Inc</b>. The stock closed 1.93% higher at $19.50 a share.</li> </ul></p><p><blockquote><ul><li>购买了 104,489 股股票，估计价值 2,130 万美元<b>Roku公司</b>在蘸酱上。该股周三收盘下跌 7.95%，至每股 203.94 美元。</li><li>购买了 705,660 股股票，估计价值 1,370 万美元<b>罗宾汉市场公司</b>该股收盘上涨 1.93%，至每股 19.50 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","ARKK":"ARK Innovation ETF","ARKW":"ARK Next Generation Internet ETF","ROKU":"Roku Inc","HOOD":"Robinhood","XPEV":"小鹏集团","ARKQ":"ARK Autonomous Technology & Robotics ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191022113","content_text":"Cathie Wood-led Ark Invest on Wednesday sold 90,455 shares — estimated to be worth $88.3 million — in Tesla Inc, booking profit in the stock as it rose after days of losses.\nThe stock pared earlier losses to close 1.82% higher at $975.99 a share on Wednesday. The Elon Musk-led company’s shares are up about 34% so far this year and down about 7.5% over the past month.\nArk Invest sold the shares via the Ark Innovation ETF(BATS:ARKK), the Ark Autonomous Technology & Robotics ETF(BATS:ARKQ) and the Ark Next Generation Internet ETF(BATS:ARKW) on Wednesday.\nTesla’s weight in ARKK and ARKW had already slipped below the 10% threshold at 8.14% and 9.35%, respectively, ahead of Wednesday’s trade. In ARKQ, it constituted 10.59% of the portfolio.\nThe three ETFs held 1.99 million shares — worth $1.91 billion — in Tesla, ahead of Wednesday’s trade.\nArk Invest has been booking profit in Tesla since September — selling over $3 billion worth of shares — after years of piling up shares in the electric vehicle company at far lower levels.\nTesla continues to be the firm's biggest bet across ETFs — a stock it predicts would hit the $3,000 mark by the end of 2025.\nWood favors the automotive industry’s switch to electric vehicles and earlier thismonth started buying sharesin the U.S. listed Chinese electric automaker Xpeng Inc.\nHere are the other key trades on Wednesday:\n\nBought 104,489 shares — estimated to be worth $21.3 million — in Roku Inc on the dip. The stock closed 7.95% lower at $203.94 a share on Wednesday.\nBought 705,660 shares — estimated to be worth $13.7 million — in Robinhood Markets Inc. The stock closed 1.93% higher at $19.50 a share.","news_type":1,"symbols_score_info":{"HOOD":0.9,"XPEV":0.9,"ARKK":0.9,"ARKW":0.9,"ROKU":0.9,"ARKQ":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690335703,"gmtCreate":1639632201836,"gmtModify":1639632202079,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"hurray","listText":"hurray","text":"hurray","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690335703","repostId":"1117904160","repostType":2,"repost":{"id":"1117904160","kind":"news","pubTimestamp":1639620135,"share":"https://www.laohunote.com/m/news/1117904160?lang=zh_CN&edition=full","pubTime":"2021-12-16 10:02","market":"us","language":"en","title":"Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117904160","media":"InvestorPlace","summary":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s ","content":"<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（NYSE:NIO）日即将到来，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio Day 2022: 13 Things for Nio Stock Investors to Expect on Dec. 18<blockquote>2022 年蔚来日：12 月 18 日蔚来股票投资者值得期待的 13 件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-16 10:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about. Let’s dive into all the latest news that traders of NIO stock need to know about today.  First off, it ...</p><p><blockquote><div>蔚来（NYSE:NIO）日即将到来，投资者有很多值得兴奋的事情。让我们深入了解蔚来股票交易者今天需要了解的所有最新消息。首先，它……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://investorplace.com/2021/12/nio-day-2022-13-things-for-nio-stock-investors-to-expect-on-dec-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117904160","content_text":"Nio(NYSE:NIO) Day is quickly approaching and there’s a lot for investors to be excited about.\nLet’s dive into all the latest news that traders of NIO stock need to know about today.\n\nFirst off, it looks like Nio Day will see the company revealing several new electric vehicles (EVs).\nThat includes a possible two new vehicle models, as well as a new vehicle brand.\nCurrent rumors claim one of the new vehicles in the ET5.\nThis is a mid-size sedan that will likely compete with other EVs on the market at a lower price than the ET7.\nTalk about the ET5 continues to heat up today after the EV company shared an image on its website.\nThis shows the outline of a still-unnamed vehicle from the company and many believe it to be the ET5.\nThere’s also talk of a potential ET(, which would be a sports coupe.\n\n\nOther rumors claim we might see the company reveal a multipurpose EV as well during the event.\nOf course, investors will have to wait until Nio Day before they can truly know what the next EVs from the company are.\nLuckily, that’s not too far away.\nNio will hold its special event on December 18, which is this Saturday.\nThe reveal event will take place at the Olympic Sports Center in Suzhou, China.\nNow we just have to wait for Nio Day to get here and confirm or bust all these rumors!","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690018127,"gmtCreate":1639613230300,"gmtModify":1639613230475,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"need booster","listText":"need booster","text":"need booster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690018127","repostId":"1194155872","repostType":4,"repost":{"id":"1194155872","kind":"news","pubTimestamp":1639613035,"share":"https://www.laohunote.com/m/news/1194155872?lang=zh_CN&edition=full","pubTime":"2021-12-16 08:03","market":"us","language":"en","title":"Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194155872","media":"RTTNews","summary":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day sli","content":"<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p><p><blockquote>新加坡股市周三再次走低，此前一个交易日结束了连续两天下跌超过20点或0.7%的下跌。海峡时报指数目前略低于 3,115 点的平台位，但预计周四将再次反弹。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p><p><blockquote>FOMC货币政策会议结果公布后，亚洲市场的全球前景乐观。欧洲和美国市场稳步走高，亚洲股市也将以类似的方式开盘。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p><p><blockquote>由于房地产和工业股下跌，STI 周三小幅收低，而金融股涨跌互现。</blockquote></p><p> For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p><p><blockquote>当天，该指数在3,106.63至3,120.55之间交易后，下跌6.21点或0.20%，收于3,114.88点。成交量为8.834亿股，价值7.618亿新加坡元。下跌的有264家，上涨的有180家。</blockquote></p><p> Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p><p><blockquote>资产中，Ascendas REIT下跌0.34%，凯德综合商业信托下跌0.50%，City Developments下跌0.42%，Comfort DelGro上涨1.45%，Dairy Farm International暴跌2.42%，星展集团上涨0.19%，云顶新加坡投降0.64%，吉宝集团下跌0.39%，丰树商业信托暴跌0.98%，丰树物流信托下跌0.53%，华侨银行下跌0.27%，胜科实业下跌0.51%，新加坡航空下跌0.20%，新加坡交易所下跌0.21%，新加坡电信下跌0.41%，泰国饮料下跌0.75%，大华银行上涨0.15%，丰益国际下跌0.96%，扬子江造船、新加坡报业控股、新加坡</blockquote></p><p> The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p><p><blockquote>华尔街的领先优势总体上是积极的，因为主要股指周三开盘小幅走低，但随后在下午飙升，收盘大幅走高。</blockquote></p><p> The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p><p><blockquote>道琼斯指数飙升383.25点或1.08%，收于35927.43点，而纳斯达克指数飙升327.94点或2.15%，收于15565.58点，标普500指数上涨75.76点或1.63%，收于4709.85点。</blockquote></p><p> The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p><p><blockquote>华尔街尾盘上涨之前，美联储宣布了人们普遍预期的加快资产购买计划削减步伐的决定。美联储以通胀发展和劳动力市场进一步改善为由表示，已决定将每月净资产购买速度降低 300 亿美元，是此前宣布的每月 150 亿美元的两倍。</blockquote></p><p> The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p><p><blockquote>美联储表示，预计每月净资产购买步伐的类似降低可能是合适的，这表明该计划将于明年 3 月结束。分析师将随后的反弹部分归因于美联储没有更积极地加快停止资产购买的时间表，这让人松了一口气。</blockquote></p><p> Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p><p><blockquote>与此同时，美联储还宣布了广泛预期的决定，将联邦基金利率目标区间维持在零至0.25%。与 9 月份的唯一一次加息预测相比，央行最新预测 2022 年将加息三次。</blockquote></p><p> Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p><p><blockquote>尽管加息前景早于预期，但分析师表示，交易员对美联储最新预测提供的确定性水平的提高感到满意。</blockquote></p><p> Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p><p><blockquote>美国能源信息署 (EIA) 表示上周美国原油库存下降 460 万桶后，原油期货周三收高。1月份西德克萨斯中质原油期货收盘上涨0.14美元，或0.2%，至每桶70.87美元。</blockquote></p><p></p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market<blockquote>新加坡股市有望反弹</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-12-16 08:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.</p><p><blockquote>新加坡股市周三再次走低，此前一个交易日结束了连续两天下跌超过20点或0.7%的下跌。海峡时报指数目前略低于 3,115 点的平台位，但预计周四将再次反弹。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.</p><p><blockquote>FOMC货币政策会议结果公布后，亚洲市场的全球前景乐观。欧洲和美国市场稳步走高，亚洲股市也将以类似的方式开盘。</blockquote></p><p> The STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.</p><p><blockquote>由于房地产和工业股下跌，STI 周三小幅收低，而金融股涨跌互现。</blockquote></p><p> For the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.</p><p><blockquote>当天，该指数在3,106.63至3,120.55之间交易后，下跌6.21点或0.20%，收于3,114.88点。成交量为8.834亿股，价值7.618亿新加坡元。下跌的有264家，上涨的有180家。</blockquote></p><p> Among the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.</p><p><blockquote>资产中，Ascendas REIT下跌0.34%，凯德综合商业信托下跌0.50%，City Developments下跌0.42%，Comfort DelGro上涨1.45%，Dairy Farm International暴跌2.42%，星展集团上涨0.19%，云顶新加坡投降0.64%，吉宝集团下跌0.39%，丰树商业信托暴跌0.98%，丰树物流信托下跌0.53%，华侨银行下跌0.27%，胜科实业下跌0.51%，新加坡航空下跌0.20%，新加坡交易所下跌0.21%，新加坡电信下跌0.41%，泰国饮料下跌0.75%，大华银行上涨0.15%，丰益国际下跌0.96%，扬子江造船、新加坡报业控股、新加坡</blockquote></p><p> The lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.</p><p><blockquote>华尔街的领先优势总体上是积极的，因为主要股指周三开盘小幅走低，但随后在下午飙升，收盘大幅走高。</blockquote></p><p> The Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&amp;P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.</p><p><blockquote>道琼斯指数飙升383.25点或1.08%，收于35927.43点，而纳斯达克指数飙升327.94点或2.15%，收于15565.58点，标普500指数上涨75.76点或1.63%，收于4709.85点。</blockquote></p><p> The late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.</p><p><blockquote>华尔街尾盘上涨之前，美联储宣布了人们普遍预期的加快资产购买计划削减步伐的决定。美联储以通胀发展和劳动力市场进一步改善为由表示，已决定将每月净资产购买速度降低 300 亿美元，是此前宣布的每月 150 亿美元的两倍。</blockquote></p><p> The Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.</p><p><blockquote>美联储表示，预计每月净资产购买步伐的类似降低可能是合适的，这表明该计划将于明年 3 月结束。分析师将随后的反弹部分归因于美联储没有更积极地加快停止资产购买的时间表，这让人松了一口气。</blockquote></p><p> Meanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.</p><p><blockquote>与此同时，美联储还宣布了广泛预期的决定，将联邦基金利率目标区间维持在零至0.25%。与 9 月份的唯一一次加息预测相比，央行最新预测 2022 年将加息三次。</blockquote></p><p> Despite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.</p><p><blockquote>尽管加息前景早于预期，但分析师表示，交易员对美联储最新预测提供的确定性水平的提高感到满意。</blockquote></p><p> Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.</p><p><blockquote>美国能源信息署 (EIA) 表示上周美国原油库存下降 460 万桶后，原油期货周三收高。1月份西德克萨斯中质原油期货收盘上涨0.14美元，或0.2%，至每桶70.87美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3249611/rebound-anticipated-for-singapore-stock-market.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194155872","content_text":"The Singapore stock market headed south again on Wednesday, one session after ending the two-day slide in which it had fallen more than 20 points or 0.7 percent. The Straits Times Index now sits just beneath the 3,115-point plateau although it figures to bounce higher again on Thursday.\nThe global forecast for the Asian markets is upbeat following results of the FOMC's monetary policy meeting. The European and U.S. markets were solidly higher and the Asian bourses figure to open in similar fashion.\nThe STI finished modestly lower on Wednesday following losses from the properties and industrials, while the financials were mixed.\nFor the day, the index slid 6.21 points or 0.20 percent to finish at 3,114.88 after trading between 3,106.63 and 3,120.55. Volume was 883.4 million shares worth 761.8 million Singapore dollars. There were 264 decliners and 180 gainers.\nAmong the actives, Ascendas REIT lost 0.34 percent, while CapitaLand Integrated Commercial Trust retreated 0.50 percent, City Developments sank 0.42 percent, Comfort DelGro jumped 1.45 percent, Dairy Farm International plummeted 2.42 percent, DBS Group rose 0.19 percent, Genting Singapore surrendered 0.64 percent, Keppel Corp shed 0.39 percent, Mapletree Commercial Trust plunged 0.98 percent, Mapletree Logistics Trust declined 0.53 percent, Oversea-Chinese Banking Corporation fell 0.27 percent, SembCorp Industries skidded 0.51 percent, Singapore Airlines dipped 0.20 percent, Singapore Exchange slid 0.21 percent, SingTel dropped 0.41 percent, Thai Beverage tumbled 0.75 percent, United Overseas Bank collected 0.15 percent, Wilmar International tanked 0.96 percent and Yangzijiang Shipbuilding, Singapore Press Holdings, Singapore Technologies Engineering and SATS were unchanged.\nThe lead from Wall Street is broadly positive as the major averages opened slightly lower on Wednesday but then surged in the afternoon to finish sharply higher.\nThe Dow soared 383.25 points or 1.08 percent to finish at 35,927.43, while the NASDAQ spiked 327.94 points or 2.15 percent to end at 15,565.58 and the S&P 500 jumped 75.76 points or 1.63 percent to close at 4,709.85.\nThe late-day rally on Wall Street came after the Fed announced its widely expected decision to accelerate the pace of reductions to its asset purchases program. Citing inflation developments and further improvement in the labor market, the Fed said it has decided to reduce the monthly pace of its net asset purchases by $30 billion per month, double the previously announced $15 billion per month.\nThe Fed said it expects similar reductions in the pace of net asset purchases will likely be appropriate each month, pointing to an end to the program next March. Analysts partly attributed the subsequent rally to relief that the Fed was not more aggressive in accelerating the timetable for halting its asset purchases.\nMeanwhile, the Fed also announced its widely expected decision to keep the target range for the federal funds rate at zero to 0.25 percent. The central bank's latest projections forecast as many three rate hikes in 2022 compared to the lone rate hike forecast in September.\nDespite the prospect of sooner than expected rate hikes, analysts suggested traders were pleased with the increased level of certainty provided by the Fed's latest projections.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) said crude inventories in the U.S. dropped by 4.6 million barrels last week. West Texas Intermediate crude oil futures for January ended up by $0.14 or 0.2 percent at $70.87 a barrel.","news_type":1,"symbols_score_info":{"STI.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":1189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090796,"gmtCreate":1639090444622,"gmtModify":1639090444779,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605090796","repostId":"1113203379","repostType":4,"repost":{"id":"1113203379","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639061813,"share":"https://www.laohunote.com/m/news/1113203379?lang=zh_CN&edition=full","pubTime":"2021-12-09 22:56","market":"us","language":"en","title":"Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘交易中下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113203379","media":"Tiger Newspress","summary":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining","content":"<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p><p><blockquote>加密股票在早盘交易中下跌.暴动区块链、马拉松数字、SoS有限公司、比特币基地、比特矿业、迦南、亿邦国际、Square、比特数字、The9和PayPal下跌2%至8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks dipped in morning trading<blockquote>加密货币股票早盘交易中下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks dipped in morning trading<blockquote>加密货币股票早盘交易中下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.</p><p><blockquote>加密股票在早盘交易中下跌.暴动区块链、马拉松数字、SoS有限公司、比特币基地、比特矿业、迦南、亿邦国际、Square、比特数字、The9和PayPal下跌2%至8%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/bf3f2d610b479a57d75ff6df427bcd26\" tg-width=\"412\" tg-height=\"656\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113203379","content_text":"Crypto stocks dipped in morning trading.Riot Blockchain,Marathon Digital,SoS Ltd,Coinbase,BIT Mining,Canaan,Ebang international,Square,Bit Digital,The9 and PayPal fell between 2% and 8%.","news_type":1,"symbols_score_info":{"RIOT":0.9}},"isVote":1,"tweetType":1,"viewCount":1361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605090515,"gmtCreate":1639090391250,"gmtModify":1639090391439,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605090515","repostId":"1165217477","repostType":4,"repost":{"id":"1165217477","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639067136,"share":"https://www.laohunote.com/m/news/1165217477?lang=zh_CN&edition=full","pubTime":"2021-12-10 00:25","market":"us","language":"en","title":"Grab and Lucid stocks plunged more than 10%<blockquote>Grab 和 Lucid 股价暴跌超过 10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165217477","media":"Tiger Newspress","summary":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","content":"<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab 和 Lucid 股价在周四的交易中暴跌超过 10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab and Lucid stocks plunged more than 10%<blockquote>Grab 和 Lucid 股价暴跌超过 10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab and Lucid stocks plunged more than 10%<blockquote>Grab 和 Lucid 股价暴跌超过 10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 00:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab and Lucid stocks plunged more than 10% in Thursday's trading.</p><p><blockquote>Grab 和 Lucid 股价在周四的交易中暴跌超过 10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ff3dbe26b3f4c86357541ed2ff3d7bfe\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c38542f4d2e6fa7aceb9fdf2aeb694ab\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165217477","content_text":"Grab and Lucid stocks plunged more than 10% in Thursday's trading.","news_type":1,"symbols_score_info":{"GRAB":0.9,"LCID":0.9}},"isVote":1,"tweetType":1,"viewCount":1354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603122557,"gmtCreate":1638376688184,"gmtModify":1638376715328,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"coming up soon","listText":"coming up soon","text":"coming up soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603122557","repostId":"1187123549","repostType":2,"repost":{"id":"1187123549","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638370614,"share":"https://www.laohunote.com/m/news/1187123549?lang=zh_CN&edition=full","pubTime":"2021-12-01 22:56","market":"us","language":"en","title":"Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价上涨至下跌4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1187123549","media":"Tiger Newspress","summary":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced it","content":"<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p><p><blockquote>小鹏汽车股价在早盘交易中上涨至下跌4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p><p><blockquote>小鹏汽车今天公布了 2021 年 11 月的汽车交付结果。</blockquote></p><p> XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p><p><blockquote>小鹏汽车在全球供应链挑战中实现了月度交付目标，11月份交付了15,613辆智能电动汽车，同比增长270%。在全球供应链各个方面持续面临挑战的情况下，强劲的交付势头证明了小鹏智能电动汽车的竞争力和稳定的执行力。</blockquote></p><p> Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p><p><blockquote>11月份交付了7,839辆P7智能运动轿车，同比增长187%。P5智能家庭轿车于2021年9月推出，11月交付了2,154辆，积压了稳定的订单。与此同时，2021 年 7 月推出的 G3i 智能 SUV 正在获得越来越多的客户关注，11 月份交付了 5,546 辆（加上 74 辆 G3 交付）。</blockquote></p><p> As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p><p><blockquote>截至2021年11月30日，年初至今车辆总交付量达到82,155辆，同比增长285%，其中P7交付量为53,110辆。</blockquote></p><p> The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p><p><blockquote>截至 2021 年 11 月底，该公司累计交付量达到 121,953 台。</blockquote></p><p> In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p><p><blockquote>11 月，小鹏汽车发布了新款旗舰智能 SUV G9，这是该公司的第四款量产车型，也是首款按照国际安全和环保标准设计的车型。这也是小鹏汽车首款采用一系列突破性内部技术的量产车型，包括 X-EEA 3.0 电子电气架构、最新的 XPILOT 4.0 高级驾驶辅助系统以及下一代 XPower 3.0 动力总成和增压系统。该公司计划于 2022 年第三季度开始交付 G9。</blockquote></p><p> XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p><p><blockquote>小鹏一直在扩大其在中国的超级充电网络，截至2021年10月31日，全国共有550个品牌超级充电站投入运营。小鹏汽车客户现在可以通过遍布中国的1,734个充电站网络享受免费的超级充电和快速充电服务。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价上涨至下跌4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors shares changed from up to down by 4%<blockquote>小鹏汽车股价上涨至下跌4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-01 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Xpeng Motors shares changed from up to down by 4%&nbsp;in morning trading.</p><p><blockquote>小鹏汽车股价在早盘交易中上涨至下跌4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b410bb36e06e8b1a13514fa0a4ee9cf0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> XPeng Inc.&nbsp;today announced its vehicle delivery results for November 2021.</p><p><blockquote>小鹏汽车今天公布了 2021 年 11 月的汽车交付结果。</blockquote></p><p> XPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.</p><p><blockquote>小鹏汽车在全球供应链挑战中实现了月度交付目标，11月份交付了15,613辆智能电动汽车，同比增长270%。在全球供应链各个方面持续面临挑战的情况下，强劲的交付势头证明了小鹏智能电动汽车的竞争力和稳定的执行力。</blockquote></p><p> Deliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).</p><p><blockquote>11月份交付了7,839辆P7智能运动轿车，同比增长187%。P5智能家庭轿车于2021年9月推出，11月交付了2,154辆，积压了稳定的订单。与此同时，2021 年 7 月推出的 G3i 智能 SUV 正在获得越来越多的客户关注，11 月份交付了 5,546 辆（加上 74 辆 G3 交付）。</blockquote></p><p> As of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.</p><p><blockquote>截至2021年11月30日，年初至今车辆总交付量达到82,155辆，同比增长285%，其中P7交付量为53,110辆。</blockquote></p><p> The Company’s cumulative deliveries reached 121,953 as of the end of November 2021.</p><p><blockquote>截至 2021 年 11 月底，该公司累计交付量达到 121,953 台。</blockquote></p><p> In November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.</p><p><blockquote>11 月，小鹏汽车发布了新款旗舰智能 SUV G9，这是该公司的第四款量产车型，也是首款按照国际安全和环保标准设计的车型。这也是小鹏汽车首款采用一系列突破性内部技术的量产车型，包括 X-EEA 3.0 电子电气架构、最新的 XPILOT 4.0 高级驾驶辅助系统以及下一代 XPower 3.0 动力总成和增压系统。该公司计划于 2022 年第三季度开始交付 G9。</blockquote></p><p> XPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.</p><p><blockquote>小鹏一直在扩大其在中国的超级充电网络，截至2021年10月31日，全国共有550个品牌超级充电站投入运营。小鹏汽车客户现在可以通过遍布中国的1,734个充电站网络享受免费的超级充电和快速充电服务。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187123549","content_text":"Xpeng Motors shares changed from up to down by 4% in morning trading.\n\nXPeng Inc. today announced its vehicle delivery results for November 2021.\nXPeng reached the monthly delivery target amidst global supply chain challenges with 15,613 Smart EVs delivered in November, representing a 270% increase year-over-year. The robust delivery momentum bears witness to the competitiveness of XPeng’s Smart EVs and steady execution in light of the ongoing challenges in various aspects of the global supply chain.\nDeliveries in November consisted of 7,839 P7 smart sports sedans, representing a 187% increase year-over-year. The P5 smart family sedan, launched in September 2021, has been building a solid order backlog with 2,154 units delivered in November. At the same time, the G3i smart SUV – launched in July 2021 - is gaining increasing customer traction with 5,546 units delivered in November (plus 74 G3s delivered).\nAs of November 30, 2021, year-to-date total vehicle deliveries reached 82,155, representing a 285% increase year-over-year, including 53,110 P7 deliveries.\nThe Company’s cumulative deliveries reached 121,953 as of the end of November 2021.\nIn November, XPeng unveiled its new flagship smart SUV, the G9, the Company’s fourth production model and its first model to be designed according to international safety and environmental protection standards. It is also XPeng’s first production model to incorporate a set of groundbreaking in-house technologies, including the X-EEA 3.0 electronic and electric architecture, the latest XPILOT 4.0 advanced driver assistance system and the next-generation XPower 3.0 powertrain and supercharging system. The Company plans to begin deliveries of the G9 in the third quarter of 2022.\nXPeng has been expanding its supercharging network across China, with 550 branded supercharging stations in operation nationwide as of October 31, 2021. XPeng customers can now enjoy free supercharging and fast charging services through a network of 1,734 charging stations across China.","news_type":1,"symbols_score_info":{"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohunote.com/m/news/1192203085?lang=zh_CN&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&amp;Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&amp;Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-30 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&amp;Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&amp;Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609604793,"gmtCreate":1638274097547,"gmtModify":1638274097637,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"think again","listText":"think again","text":"think again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609604793","repostId":"2187947581","repostType":4,"isVote":1,"tweetType":1,"viewCount":1052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609605147,"gmtCreate":1638273926952,"gmtModify":1638273927084,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"enjoy wen it go up","listText":"enjoy wen it go up","text":"enjoy wen it go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609605147","repostId":"1164097100","repostType":2,"repost":{"id":"1164097100","kind":"news","pubTimestamp":1638237374,"share":"https://www.laohunote.com/m/news/1164097100?lang=zh_CN&edition=full","pubTime":"2021-11-30 09:56","market":"us","language":"en","title":"AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票 NFT 赠品的 AMC 股票趋势</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1164097100","media":"InvestorPlace","summary":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is","content":"<p><div> AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible ...</p><p><blockquote><div>AMC院线（纽约证券交易所股票代码：AMC）正在押注一位超级英雄——蜘蛛侠。事实上，在连锁影院宣布将赠送86,000部不可替代影片后，AMC股票再次成为焦点……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票 NFT 赠品的 AMC 股票趋势</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Trends on NFT Giveaway for Marvel Spider-Man Tickets<blockquote>漫威蜘蛛侠门票 NFT 赠品的 AMC 股票趋势</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-11-30 09:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible ...</p><p><blockquote><div>AMC院线（纽约证券交易所股票代码：AMC）正在押注一位超级英雄——蜘蛛侠。事实上，在连锁影院宣布将赠送86,000部不可替代影片后，AMC股票再次成为焦点……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/11/amc-stock-trends-on-nft-giveaway-for-marvel-spider-man-tickets/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164097100","content_text":"AMC Entertainment(NYSE:AMC) is placing its bets on one super hero, Spider-Man. In fact, AMC stock is once again in focus after the theater chain announced it would give out86,000 non-fungible tokenswith Marvel Spider-Man: No Way Hometickets. The combo of meme stock and NFTs certainly has investors watching!\nSo what do you need to know?\nAMC is truly breaking new ground with its first-ever NFT promotion. A joint effort between Sony Pictures and AMC, the collaboration will yield roughly 90,000 NFTs. The NFTs will go to a limited number of ticket buyers for the Dec. 16 premier.\nNow, there are some other conditions investors should note. To qualify for the NFTs, buyers must be members of AMC Stubs A-list, Stubs Premiere or AMC Investor Connect on the AMC website. Buyers must have their Stubs account number associated with the purchase, and their ticket must be scanned upon entrance to the movie. In addition, the NFTs must be redeemed by March 1.\nDespite the enticing offer, AMC stock was fairly unresponsive to the news, down 2% on the day.\nCan AMC Stock Overcome Its Meme-ified Past?\nAMC remains hopeful that it can entice the NFT bulls, and Spider-Man may be just the person it needs. Adam Aron, CEO of AMC,commented onthe giveaway and said this:\n\n “… the incredibly talented artists at Cub Studios are creating more than 100 unique NFTs giving appropriate respect to this most recent incarnation of the timeless and ever so popular Spider-Man franchise. For those members of our AMC Stubs A-List, AMC Stubs Premiere and AMC Investor Connect program who are among the first to purchase or reserve their ticket to opening day at AMC, this unprecedented Spider-Man NFT is truly a ticket-purchase gift like nothing we’ve ever offered before. … So, my advice is to get your Spider-Man tickets as quickly as you can.”\n\nAMC believes it can turn around its tumultuous past by calling in a crypto lifeline. If the moves catch the gaze of the Reddit bulls, it certainly remains a possibility.\nWith AMC currently at $36.84, it remains to be seen how much movement the NFT offer will grant it. One thing for sure is that all eyes are on AMC stock prices heading into the December premier.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126513,"gmtCreate":1637746134207,"gmtModify":1637746138028,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"themes":[],"title":"","htmlText":"enjoy the holiday","listText":"enjoy the holiday","text":"enjoy the holiday","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126513","repostId":"1151702113","repostType":4,"repost":{"id":"1151702113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637559387,"share":"https://www.laohunote.com/m/news/1151702113?lang=zh_CN&edition=full","pubTime":"2021-11-22 13:36","market":"us","language":"en","title":"Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：美国股市将于周四感恩节休市，周五提前三小时休市</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151702113","media":"Tiger Newspress","summary":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, includ","content":"<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p><p><blockquote>11月25日（本周四）是感恩节。包括美股在内的美国所有金融市场将休市一天。</blockquote></p><p> On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p><p><blockquote>11月26日（本周五），纳斯达克和纽约证券交易所将于美国东部时间下午1点（北京时间/周六凌晨2点）收盘，交易时间为北京时间22:30-次日2:00。所以会比正常关门时间提前3个小时。</blockquote></p><p> Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p><p><blockquote>中国、英国、澳大利亚和新加坡的股票将照常交易。</blockquote></p><p> <b>Background</b></p><p><blockquote><b>背景</b></blockquote></p><p> Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p><p><blockquote>感恩节是美国、加拿大、格林纳达、圣卢西亚和利比里亚在不同日期庆祝的全国性节日。这一天开始是为了丰收和前一年的祝福而感谢和牺牲的一天。德国和日本也有类似命名的节日假期。感恩节在加拿大10月的第二个星期一庆祝，在美国11月的第四个星期四庆祝，在其他地方大约在一年中的同一时间庆祝。</blockquote></p><p> Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p><p><blockquote>黑色星期五是美国感恩节后的星期五的口语术语。许多商店以折扣价提供高度促销的销售，并且经常很早开门，有时早在午夜甚至感恩节。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：美国股市将于周四感恩节休市，周五提前三小时休市</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: U.S. stocks will be closed on Thursday for Thanksgiving day,and close three hours earlier on Friday<blockquote>提醒：美国股市将于周四感恩节休市，周五提前三小时休市</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-22 13:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>November 25th&nbsp;(this&nbsp;Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.</p><p><blockquote>11月25日（本周四）是感恩节。包括美股在内的美国所有金融市场将休市一天。</blockquote></p><p> On November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at&nbsp;U.S.&nbsp;Eastern Time&nbsp;1 p.m.(Beijing time/SGT&nbsp;2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.</p><p><blockquote>11月26日（本周五），纳斯达克和纽约证券交易所将于美国东部时间下午1点（北京时间/周六凌晨2点）收盘，交易时间为北京时间22:30-次日2:00。所以会比正常关门时间提前3个小时。</blockquote></p><p> Stocks&nbsp;in&nbsp;China,Britain, Australia&nbsp;and Singapore&nbsp;will&nbsp;trade as usual.</p><p><blockquote>中国、英国、澳大利亚和新加坡的股票将照常交易。</blockquote></p><p> <b>Background</b></p><p><blockquote><b>背景</b></blockquote></p><p> Thanksgiving&nbsp;Day&nbsp;is a national&nbsp;holiday&nbsp;celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the&nbsp;harvest&nbsp;and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving&nbsp;Day&nbsp;is celebrated on the&nbsp;second Monday of October&nbsp;in Canada and on the&nbsp;fourth Thursday of November&nbsp;in the United States and around the same part of the year in other places.&nbsp;</p><p><blockquote>感恩节是美国、加拿大、格林纳达、圣卢西亚和利比里亚在不同日期庆祝的全国性节日。这一天开始是为了丰收和前一年的祝福而感谢和牺牲的一天。德国和日本也有类似命名的节日假期。感恩节在加拿大10月的第二个星期一庆祝，在美国11月的第四个星期四庆祝，在其他地方大约在一年中的同一时间庆祝。</blockquote></p><p> Black Friday&nbsp;is a colloquial term for the Friday following&nbsp;Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight&nbsp;or even on Thanksgiving Day.</p><p><blockquote>黑色星期五是美国感恩节后的星期五的口语术语。许多商店以折扣价提供高度促销的销售，并且经常很早开门，有时早在午夜甚至感恩节。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/af950d731994581f416aa413e17585d3\" tg-width=\"450\" tg-height=\"281\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151702113","content_text":"November 25th (this Thursday) is Thanksgiving Day.All financial markets in the United States, including U.S. stocks, will be closed for one day.\nOn November 26th(this Friday), the Nasdaq and New York Stock Exchange end trading at U.S. Eastern Time 1 p.m.(Beijing time/SGT 2 am on Saturday),and the trading hours will be 22:30 Beijing time-2:00 the next day.So it will be 3 hours ahead of the regular closing time.\nStocks in China,Britain, Australia and Singapore will trade as usual.\nBackground\nThanksgiving Day is a national holiday celebrated on various dates in the United States, Canada, Grenada, Saint Lucia, and Liberia. It began as a day of giving thanks and sacrifice for the blessing of the harvest and of the preceding year. Similarly named festival holidays occur in Germany and Japan. Thanksgiving Day is celebrated on the second Monday of October in Canada and on the fourth Thursday of November in the United States and around the same part of the year in other places. \nBlack Friday is a colloquial term for the Friday following Thanksgiving Day in the United States. Many stores offer highly promoted sales at discounted prices and often open very early, sometimes as early as midnight or even on Thanksgiving Day.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698851243,"gmtCreate":1640347676382,"gmtModify":1640347676614,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"pls like","listText":"pls like","text":"pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698851243","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":4185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886431093,"gmtCreate":1631613822012,"gmtModify":1631890295712,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/886431093","repostId":"1160275332","repostType":4,"repost":{"id":"1160275332","kind":"news","pubTimestamp":1631604098,"share":"https://www.laohunote.com/m/news/1160275332?lang=zh_CN&edition=full","pubTime":"2021-09-14 15:21","market":"us","language":"en","title":"Busy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的 IPO 市场有望使 2021 年成为有史以来收益最大的一年</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160275332","media":"MarketWatch","summary":"Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit th","content":"<p>Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week </p><p><blockquote>由罗杰·费德勒和得来速咖啡连锁店支持的瑞士跑鞋公司预计将于本周上市</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18111af5f5bda21b3128860fe616c5ca\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Swiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.</span></p><p><blockquote><p class=\"t-img-caption\"><span>瑞士网球巨人罗杰·费德勒是本周最大的IPO之一的支持者。</span></p></blockquote></p><p> After a flurry of initial-public-offering launches last week&nbsp;set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. </p><p><blockquote>在上周一系列首次公开募股启动让市场陷入繁忙的交易量下跌之后，预计本周将有 11 家公司定价并筹集超过 30 亿美元的收益。</blockquote></p><p> If all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. </p><p><blockquote>机构研究和交易所交易基金提供商 Renaissance Capital 的创始人兼首席执行官比尔·史密斯 (Bill Smith) 表示，如果所有交易都能实现，2021 年将成为有史以来 IPO 收益最大的一年，并打破之前的记录约 30%。据 Renaissance 称，今年市场预计将达成约 375 笔交易，筹集 1250 亿美元，超过 2000 年互联网繁荣时期筹集的 970 亿美元。</blockquote></p><p> “After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. </p><p><blockquote>“史密斯在一篇市场评论中写道：”在漫长的暑假之后，本周是即将到来的科技、生物技术和消费品 IPO 的试金石。这份名单包括一家由网球巨头罗杰·费德勒支持的瑞士跑鞋公司、一家免下车咖啡亭运营商以及一家从保险公司 Genworth Financial 分拆出来的抵押贷款保险公司。</blockquote></p><p> The biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.</p><p><blockquote>本周最大的交易预计将来自总部位于芝加哥的技术咨询公司 Thoughtworks，该公司将以高达 61 亿美元的估值上市。</blockquote></p><p> The company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.</p><p><blockquote>该公司预计在 IPO 完成后将名称从 Turing Holding Corp. 更名为 Thoughtworks，并表示将发行总计 3684 万股股票，分配给公司和出售股东。</blockquote></p><p> The deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.</p><p><blockquote>预计交易价格将在每股 18 美元至 20 美元之间，股票将在纳斯达克交易，股票代码为 “TWKS”。高盛和摩根大通是主承销商。该公司 2020 年收入为 8.034 亿美元，净利润为 7930 万美元，而 2019 年收入为 7.722 亿美元，净利润为 2840 万美元。</blockquote></p><p> The Swiss athletic-footwear maker On Holding&nbsp;is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”</p><p><blockquote>这家持股的瑞士运动鞋制造商预计将以近 60 亿美元的估值筹集高达 6.22 亿美元的资金。On 已申请在纽约证券交易所上市 3110 万股股票，每股定价为 18 至 20 美元，股票代码为 “ONON”。</blockquote></p><p> Goldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.</p><p><blockquote>高盛、摩根士丹利和摩根士丹利是这笔交易的九家银行组成的银团的主承销商。所得款项将用于一般公司用途。该公司有一条与费德勒共同开发的产品线。</blockquote></p><p> The company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period,&nbsp;according to its IPO documents.&nbsp;Sales came to 315.5 million francs, up from 170.9 million francs.</p><p><blockquote>根据其首次公开募股文件，该公司在截至 6 月 30 日的六个月中净利润为 380 万瑞士法郎（约合 410 万美元），而去年同期亏损 3310 万法郎。销售额从 1.709 亿法郎增至 3.155 亿法郎。</blockquote></p><p> Also from Switzerland, sports betting site Sportrader Group AG&nbsp;plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.</p><p><blockquote>同样来自瑞士的体育博彩网站Sportrader Group AG计划发行1900万股股票，每股定价25至28美元，估值高达310亿美元。该公司已申请在纳斯达克上市，股票代码为 “SRAD”。摩根大通、摩根士丹利、花旗集团和瑞银是参与该交易的 13 家银行财团的主承销商。</blockquote></p><p> Proceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million,&nbsp;according to its filing documents.</p><p><blockquote>所得款项将用作营运资金和刺激增长。根据其备案文件，该公司今年前六个月净利润为 2990 万美元，收入为 3.21 亿美元。</blockquote></p><p> Dutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.</p><p><blockquote>Dutch Bros Inc. 是一家主要在美国西部各州提供冷热饮料的免下车商店运营商，计划在 IPO 中发行 2110 万股股票，每股定价为 18 至 20 美元，公司估值高达 33 亿美元。</blockquote></p><p> BofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”</p><p><blockquote>美国银行证券、摩根大通和杰富瑞是参与该交易的 13 家银行财团的主承销商。该公司已申请在纽约证券交易所上市，股票代码为 “BROS.</blockquote></p><p> Proceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.</p><p><blockquote>所得款项将用于购买额外的 A 类股票——该公司计划持有四类具有不同投票权的股票。该公司今年前六个月净亏损 1,360 万美元，即每股亏损 32 美分，低于去年同期公布的 1,650 万美元，即每股亏损 38 美分。收入从 3.274 亿美元降至 2.279 亿美元。</blockquote></p><p> <b>Rounding out the list are:</b></p><p><blockquote><b>最后一个列表是：</b></blockquote></p><p> •&nbsp;Definitive Healthcare Corp.,&nbsp;a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.</p><p><blockquote>- 总部位于马萨诸塞州的医疗保健商业智能提供商 Definitive Healthcare Corp. 计划在其 PO 中发行 1556 万股股票，预计每股价格在 21 至 24 美元之间。按照这个定价，该公司的估值可能高达 35.5 亿美元。</blockquote></p><p></p><p> •&nbsp;Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.</p><p><blockquote>- Genworth 旗下的抵押贷款保险公司 Enact Holdings Inc. 计划发行 1330 万股股票，每股定价为 19 至 20 美元。该公司的估值最高时为 33 亿美元。该公司表示，所有股份将由Genworth出售，不会获得任何收益。该公司已申请在纳斯达克上市，股票代码为 “ACT”。高盛和摩根大通是参与该交易的九家银行团队的主承销商。</blockquote></p><p> •&nbsp;ForgeRock<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>&nbsp;a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.</p><p><blockquote>• 假摇滚<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>总部位于加利福尼亚州的身份安全平台希望通过发行 1100 万股股票来筹集高达 2.64 亿美元的资金，每股价格在 21 美元至 24 美元之间。该定价将使该公司估值高达 19.1 亿美元。</blockquote></p><p> The stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.</p><p><blockquote>该股预计将在纽约证券交易所上市，股票代码为 “FORG ”。摩根士丹利和摩根大通是主承销商。该公司 2020 年收入为 1.276 亿美元，净亏损 4180 万美元，而 2019 年收入为 1.045 亿美元，亏损 3690 万美元。</blockquote></p><p> <b>•</b>Dice Therapeutics&nbsp;is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.</p><p><blockquote><b>•</b>Dice Therapeutics 预计将以高达 5.83 亿美元的估值筹集高达 1.7 亿美元的资金，并在纳斯达克上市，股票代码为 “DICE ”。生物技术正在开发治疗免疫学领域慢性疾病的疗法。</blockquote></p><p> <b>•</b>Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.</p><p><blockquote><b>•</b>手术机器人开发商 Procept BioRobotics 的目标是以约 10 亿美元的估值筹集至多 1.32 亿美元，计划在纳斯达克上市，股票代码为 “PRCT”。美国银行证券和高盛是主承销商。</blockquote></p><p> “We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.</p><p><blockquote>“该公司在 IPO 文件中表示：”我们开发、制造和销售 AquaBeam 机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初的重点是治疗良性前列腺增生（BPH）。</blockquote></p><p> <b>•</b>Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”</p><p><blockquote><b>•</b>Tyra Biosciences 的目标是以 5.89 亿美元的估值筹集 1.072 亿美元的 IPO 收益。该生物技术公司的主要候选产品是治疗膀胱癌的药物。它已申请在纳斯达克上市，代码为 “泰拉 ”。</blockquote></p><p> <b>•</b>EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.</p><p><blockquote><b>•</b>EzFill Holdings 是一家位于南佛罗里达州的基于应用程序的移动加油公司，计划以 1 亿美元的估值筹集 2500 万美元。该公司已申请在纳斯达克上市，股票代码为 “EZFL”。ThinkEquity 是独家承销商。</blockquote></p><p> The Renaissance IPO ETF&nbsp;has gained 6% to date in 2021, while the S&amp;P 500&nbsp;has advanced 19%.</p><p><blockquote>2021 年迄今为止，Renaissance IPO ETF 上涨了 6%，而标普500上涨了 19%。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Busy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的 IPO 市场有望使 2021 年成为有史以来收益最大的一年</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBusy IPO market this week poised to make 2021 the biggest year ever by proceeds<blockquote>本周繁忙的 IPO 市场有望使 2021 年成为有史以来收益最大的一年</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-09-14 15:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week </p><p><blockquote>由罗杰·费德勒和得来速咖啡连锁店支持的瑞士跑鞋公司预计将于本周上市</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/18111af5f5bda21b3128860fe616c5ca\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Swiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.</span></p><p><blockquote><p class=\"t-img-caption\"><span>瑞士网球巨人罗杰·费德勒是本周最大的IPO之一的支持者。</span></p></blockquote></p><p> After a flurry of initial-public-offering launches last week&nbsp;set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. </p><p><blockquote>在上周一系列首次公开募股启动让市场陷入繁忙的交易量下跌之后，预计本周将有 11 家公司定价并筹集超过 30 亿美元的收益。</blockquote></p><p> If all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. </p><p><blockquote>机构研究和交易所交易基金提供商 Renaissance Capital 的创始人兼首席执行官比尔·史密斯 (Bill Smith) 表示，如果所有交易都能实现，2021 年将成为有史以来 IPO 收益最大的一年，并打破之前的记录约 30%。据 Renaissance 称，今年市场预计将达成约 375 笔交易，筹集 1250 亿美元，超过 2000 年互联网繁荣时期筹集的 970 亿美元。</blockquote></p><p> “After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. </p><p><blockquote>“史密斯在一篇市场评论中写道：”在漫长的暑假之后，本周是即将到来的科技、生物技术和消费品 IPO 的试金石。这份名单包括一家由网球巨头罗杰·费德勒支持的瑞士跑鞋公司、一家免下车咖啡亭运营商以及一家从保险公司 Genworth Financial 分拆出来的抵押贷款保险公司。</blockquote></p><p> The biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.</p><p><blockquote>本周最大的交易预计将来自总部位于芝加哥的技术咨询公司 Thoughtworks，该公司将以高达 61 亿美元的估值上市。</blockquote></p><p> The company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.</p><p><blockquote>该公司预计在 IPO 完成后将名称从 Turing Holding Corp. 更名为 Thoughtworks，并表示将发行总计 3684 万股股票，分配给公司和出售股东。</blockquote></p><p> The deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.</p><p><blockquote>预计交易价格将在每股 18 美元至 20 美元之间，股票将在纳斯达克交易，股票代码为 “TWKS”。高盛和摩根大通是主承销商。该公司 2020 年收入为 8.034 亿美元，净利润为 7930 万美元，而 2019 年收入为 7.722 亿美元，净利润为 2840 万美元。</blockquote></p><p> The Swiss athletic-footwear maker On Holding&nbsp;is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”</p><p><blockquote>这家持股的瑞士运动鞋制造商预计将以近 60 亿美元的估值筹集高达 6.22 亿美元的资金。On 已申请在纽约证券交易所上市 3110 万股股票，每股定价为 18 至 20 美元，股票代码为 “ONON”。</blockquote></p><p> Goldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.</p><p><blockquote>高盛、摩根士丹利和摩根士丹利是这笔交易的九家银行组成的银团的主承销商。所得款项将用于一般公司用途。该公司有一条与费德勒共同开发的产品线。</blockquote></p><p> The company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period,&nbsp;according to its IPO documents.&nbsp;Sales came to 315.5 million francs, up from 170.9 million francs.</p><p><blockquote>根据其首次公开募股文件，该公司在截至 6 月 30 日的六个月中净利润为 380 万瑞士法郎（约合 410 万美元），而去年同期亏损 3310 万法郎。销售额从 1.709 亿法郎增至 3.155 亿法郎。</blockquote></p><p> Also from Switzerland, sports betting site Sportrader Group AG&nbsp;plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.</p><p><blockquote>同样来自瑞士的体育博彩网站Sportrader Group AG计划发行1900万股股票，每股定价25至28美元，估值高达310亿美元。该公司已申请在纳斯达克上市，股票代码为 “SRAD”。摩根大通、摩根士丹利、花旗集团和瑞银是参与该交易的 13 家银行财团的主承销商。</blockquote></p><p> Proceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million,&nbsp;according to its filing documents.</p><p><blockquote>所得款项将用作营运资金和刺激增长。根据其备案文件，该公司今年前六个月净利润为 2990 万美元，收入为 3.21 亿美元。</blockquote></p><p> Dutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.</p><p><blockquote>Dutch Bros Inc. 是一家主要在美国西部各州提供冷热饮料的免下车商店运营商，计划在 IPO 中发行 2110 万股股票，每股定价为 18 至 20 美元，公司估值高达 33 亿美元。</blockquote></p><p> BofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”</p><p><blockquote>美国银行证券、摩根大通和杰富瑞是参与该交易的 13 家银行财团的主承销商。该公司已申请在纽约证券交易所上市，股票代码为 “BROS.</blockquote></p><p> Proceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.</p><p><blockquote>所得款项将用于购买额外的 A 类股票——该公司计划持有四类具有不同投票权的股票。该公司今年前六个月净亏损 1,360 万美元，即每股亏损 32 美分，低于去年同期公布的 1,650 万美元，即每股亏损 38 美分。收入从 3.274 亿美元降至 2.279 亿美元。</blockquote></p><p> <b>Rounding out the list are:</b></p><p><blockquote><b>最后一个列表是：</b></blockquote></p><p> •&nbsp;Definitive Healthcare Corp.,&nbsp;a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.</p><p><blockquote>- 总部位于马萨诸塞州的医疗保健商业智能提供商 Definitive Healthcare Corp. 计划在其 PO 中发行 1556 万股股票，预计每股价格在 21 至 24 美元之间。按照这个定价，该公司的估值可能高达 35.5 亿美元。</blockquote></p><p></p><p> •&nbsp;Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.</p><p><blockquote>- Genworth 旗下的抵押贷款保险公司 Enact Holdings Inc. 计划发行 1330 万股股票，每股定价为 19 至 20 美元。该公司的估值最高时为 33 亿美元。该公司表示，所有股份将由Genworth出售，不会获得任何收益。该公司已申请在纳斯达克上市，股票代码为 “ACT”。高盛和摩根大通是参与该交易的九家银行团队的主承销商。</blockquote></p><p> •&nbsp;ForgeRock<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>&nbsp;a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.</p><p><blockquote>• 假摇滚<a href=\"https://www.marketwatch.com/investing/stock/FORG?mod=MW_story_quote&amp;mod=article_inline\" target=\"_blank\">,</a>总部位于加利福尼亚州的身份安全平台希望通过发行 1100 万股股票来筹集高达 2.64 亿美元的资金，每股价格在 21 美元至 24 美元之间。该定价将使该公司估值高达 19.1 亿美元。</blockquote></p><p> The stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.</p><p><blockquote>该股预计将在纽约证券交易所上市，股票代码为 “FORG ”。摩根士丹利和摩根大通是主承销商。该公司 2020 年收入为 1.276 亿美元，净亏损 4180 万美元，而 2019 年收入为 1.045 亿美元，亏损 3690 万美元。</blockquote></p><p> <b>•</b>Dice Therapeutics&nbsp;is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.</p><p><blockquote><b>•</b>Dice Therapeutics 预计将以高达 5.83 亿美元的估值筹集高达 1.7 亿美元的资金，并在纳斯达克上市，股票代码为 “DICE ”。生物技术正在开发治疗免疫学领域慢性疾病的疗法。</blockquote></p><p> <b>•</b>Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.</p><p><blockquote><b>•</b>手术机器人开发商 Procept BioRobotics 的目标是以约 10 亿美元的估值筹集至多 1.32 亿美元，计划在纳斯达克上市，股票代码为 “PRCT”。美国银行证券和高盛是主承销商。</blockquote></p><p> “We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.</p><p><blockquote>“该公司在 IPO 文件中表示：”我们开发、制造和销售 AquaBeam 机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初的重点是治疗良性前列腺增生（BPH）。</blockquote></p><p> <b>•</b>Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”</p><p><blockquote><b>•</b>Tyra Biosciences 的目标是以 5.89 亿美元的估值筹集 1.072 亿美元的 IPO 收益。该生物技术公司的主要候选产品是治疗膀胱癌的药物。它已申请在纳斯达克上市，代码为 “泰拉 ”。</blockquote></p><p> <b>•</b>EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.</p><p><blockquote><b>•</b>EzFill Holdings 是一家位于南佛罗里达州的基于应用程序的移动加油公司，计划以 1 亿美元的估值筹集 2500 万美元。该公司已申请在纳斯达克上市，股票代码为 “EZFL”。ThinkEquity 是独家承销商。</blockquote></p><p> The Renaissance IPO ETF&nbsp;has gained 6% to date in 2021, while the S&amp;P 500&nbsp;has advanced 19%.</p><p><blockquote>2021 年迄今为止，Renaissance IPO ETF 上涨了 6%，而标普500上涨了 19%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/busy-ipo-market-this-week-may-make-2021-the-biggest-year-for-proceeds-and-break-previous-record-by-30-11631554372?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ONON":"On Holding AG","DH":"Definitive Healthcare Corp.",".SPX":"S&P 500 Index","PRCT":"PROCEPT BioRobotics","TYRA":"Tyra Biosciences, Inc.",".DJI":"道琼斯","SRAD":"Sportradar Group AG","BROS":"Dutch Bros Inc.",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/busy-ipo-market-this-week-may-make-2021-the-biggest-year-for-proceeds-and-break-previous-record-by-30-11631554372?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160275332","content_text":"Swiss running-shoe company backed by Roger Federer and drive-through coffee chain expected to hit the market this week \nSwiss tennis giant Roger Federer is a backer of one of this week's bigger IPOs.\n\n\nAfter a flurry of initial-public-offering launches last week set the market up for a busy fall for deals, 11 are expected to price this week and raise more than $3 billion in proceeds. \n\nIf all deals materialize, it will make 2021 the biggest year for IPO proceeds ever, and shatter the previous record by about 30%, according to Bill Smith, founder and chief executive of Renaissance Capital, a provider of institutional research and exchange-traded funds oriented around IPOs. The market is expected to see some 375 deals for the year, raising $125 billion, according to Renaissance, beating the $97 billion raised in 2000 during the dot-com boom. \n\n“After the long summer break, this week is a litmus test for upcoming tech, biotech, and consumer IPOs,” Smith wrote in a market commentary. The list includes a Swiss running-shoe company backed by tennis giant Roger Federer, a drive-through coffee kiosk operator and a mortgage insurer that was spun out of insurer Genworth Financial. \n\nThe biggest deal of the week is expected to come from Thoughtworks,a Chicago-based technology consultancy that will go public at a valuation of up to $6.1 billion.\nThe company, which expects to change its name from Turing Holding Corp. to Thoughtworks with completion of the IPO, said a total of 36.84 million shares will be offered, split between the company and selling shareholders.\n\nThe deal is expected to price at between $18 and $20 a share, and the stock will trade on the Nasdaq under the ticker symbol “TWKS.” Goldman Sachs and JPMorgan are the lead underwriters. The company recorded net income of $79.3 million on revenue of $803.4 million in 2020, after income of $28.4 million on revenue of $772.2 million in 2019.\nThe Swiss athletic-footwear maker On Holding is expected to raise up to $622 million at a valuation of almost $6 billion. On has applied to list 31.1 million shares priced at $18 to $20 each on the New York Stock Exchange, under the ticker symbol “ONON.”\n\nGoldman Sachs, Morgan Stanley and Morgan Stanley are lead underwriters in a syndicate of nine banks on the On deal. Proceeds are to be used for general corporate purposes. The company has a line that it co-developed with Federer.\n\nThe company had net income of 3.8 million Swiss francs ($4.1 million) in the six months through June 30, after a loss of 33.1 million francs in the year-earlier period, according to its IPO documents. Sales came to 315.5 million francs, up from 170.9 million francs.\n\nAlso from Switzerland, sports betting site Sportrader Group AG plans to offer 19 million shares priced at $25 to $28 each, for a valuation of up to $31 billion. The company has applied to list on Nasdaq under the ticker symbol “SRAD.” JPMorgan, Morgan Stanley, Citigroup and UBS are lead underwriters in a syndicate of 13 banks working on the deal.\n\nProceeds are to be used for working capital and to spur growth. The company had a net profit of $29.9 million in the first six months of the year, on revenue of $321 million, according to its filing documents.\n\nDutch Bros Inc.,an operator of drive-through shops that serve hot and cold drinks mostly in western U.S. states, is planning to offer 21.1 million shares priced at $18 to $20 each in its IPO, valuing the company at up to $3.3 billion.\n\nBofA Securities, JPMorgan and Jefferies are lead underwriters in a syndicate of 13 banks working on the deal. The company has applied to list on the New York Stock Exchange under the ticker symbol “BROS.”\nProceeds are to be used to purchase additional Class A shares — the company is planning to have four classes of stock with differing voting rights. The company had a net loss of $13.6 million, or 32 cents a share, in the first six months of the year, narrower than the loss of $16.5 million, or 38 cents a share, posted in the year-earlier period. Revenue fell to $227.9 million from $327.4 million.\n\nRounding out the list are:\n• Definitive Healthcare Corp., a Massachusetts-based provider of healthcare commercial intelligence, is planning to offer 15.56 million shares in its PO, which is expected to price between $21 and $24 a share. At that pricing, the company could be valued at up to $3.55 billion.\n• Enact Holdings Inc., a mortgage insurer owned by Genworth, is planning to offer 13.3 million shares priced at $19 to $20 each. The company would be valued at $3.3 billion at the top of that range. The company said all shares will be sold by Genworth and it will not receive any proceeds. It has applied to list on Nasdaq under the ticker “ACT.” Goldman Sachs and JPMorgan are lead underwriters in a team of nine banks working on the deal.\n• ForgeRock, a California-based identity security platform, is looking to raise up to $264 million with an offering of 11 million shares priced between $21 and $24 a share. That pricing would value the company a valuation of up to $1.91 billion.\nThe stock is expected to list on the NYSE under the ticker symbol “FORG.” Morgan Stanley and JPMorgan are the lead underwriters. The company recorded a net loss of $41.8 million on revenue of $127.6 million in 2020, after a loss of $36.9 million on revenue of $104.5 million in 2019.\n•Dice Therapeutics is expected to raise up to $170 million at a valuation of up to $583 million and list on Nasdaq under the ticker symbol “DICE.” The biotech is developing therapies to treat chronic diseases in the field of immunology.\n•Surgical robotics developer Procept BioRobotics,is aiming to raise up to $132 million at a valuation of about $1 billion with plans to list on Nasdaq under the ticker symbol “PRCT.” BofA Securities and Goldman Sachs are lead underwriters.\n“We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH,” the company says in its IPO documents.\n•Tyra Biosciences is aiming to raise $107.2 million in IPO proceeds at a valuation of $589 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.”\n•EzFill Holdings, an app-based mobile fueling company in South Florida, is planning to raise $25 million at a valuation of $100 million. The company has applied to list on Nasdaq under the ticker symbol “EZFL.” ThinkEquity is sole underwriter.\nThe Renaissance IPO ETF has gained 6% to date in 2021, while the S&P 500 has advanced 19%.","news_type":1,"symbols_score_info":{".IXIC":0.9,"ACT.UK":0.9,"BROS":0.9,".DJI":0.9,"ONON":0.9,"PRCT":0.9,"DH":0.9,"DRNA":0.9,"TYRA":0.9,"TWKS":0.9,".SPX":0.9,"SRAD":0.9,"FORG":0.9}},"isVote":1,"tweetType":1,"viewCount":560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":868026688,"gmtCreate":1632556527144,"gmtModify":1632657795625,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"hope to success","listText":"hope to success","text":"hope to success","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/868026688","repostId":"1117076176","repostType":4,"isVote":1,"tweetType":1,"viewCount":641,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":148332278,"gmtCreate":1625928474894,"gmtModify":1633931523624,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like&nbsp;","listText":"like&nbsp;","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/148332278","repostId":"2150053623","repostType":4,"repost":{"id":"2150053623","kind":"highlight","pubTimestamp":1625883910,"share":"https://www.laohunote.com/m/news/2150053623?lang=zh_CN&edition=full","pubTime":"2021-07-10 10:25","market":"us","language":"en","title":"A crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美国股市经历了疯狂的一周，市场叙事发生了变化——投资者应该相信吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2150053623","media":"MarketWatch","summary":"Investors must decide whether they believe stalling economic growth is a bigger threat than an infla","content":"<p>Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge</p><p><blockquote>投资者必须决定他们是否认为经济增长停滞比通胀飙升构成更大的威胁</blockquote></p><p> <img src=\"https://static.tigerbbs.com/32ec205cf1616aaba5573cc40240a899\" tg-width=\"1260\" tg-height=\"876\"></p><p><blockquote></blockquote></p><p> Fears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right <a href=\"https://laohu8.com/S/AONE.U\">one</a> ?</p><p><blockquote>对通胀失控的担忧已经被对全球经济增长迅速放缓的担忧所取代——这使得美国投资者度过了非常漫长、假期缩短的一周——但这种新的说法正确吗<a href=\"https://laohu8.com/S/AONE.U\">一</a>?</blockquote></p><p> A Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.</p><p><blockquote>国债反弹变成了购买狂潮，导致长期收益率大幅下降。这使得所谓的通货膨胀贸易失去了任何剩余的风力，而通货膨胀贸易有利于对周期性更为敏感的公司的股票，这些公司预计将从价格上涨和经济增长加速中受益最多。</blockquote></p><p> What changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.</p><p><blockquote>有什么变化？纽约人寿投资公司 (New York Life Investments) 的经济学家兼投资组合策略师劳伦·古德温 (Lauren Goodwin) 表示，市场叙事的转变有三个重要因素，该公司管理着 6050 亿美元的资产。</blockquote></p><p> The first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.</p><p><blockquote>她表示，首先是美联储对数据的反应方式发生了明显的变化，投资者不再希望政策制定者像之前认为的那样容忍经济过热和通胀上升。第二，虽然经济增长预计将保持强劲，但增长速度预计将达到峰值。第三，有人担心导致新冠肺炎的三角洲和其他冠状病毒变种的传播可能会迫使新一轮限制，这将给全球经济活动带来压力。</blockquote></p><p> \"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"</p><p><blockquote>古德温在接受电话采访时表示：“总的来说，这与几周前的市场共识叙事截然不同，当时的焦点都是刺激和过热。”他指出，投资者现在必须问：“这种新叙事是正确的吗？”</blockquote></p><p> The real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.</p><p><blockquote>过去一周真正的痛苦在于国债市场，该市场的反弹导致长期收益率大幅下降，价格上涨。此次上涨在很大程度上归因于美国国债空头被迫做空，他们担心通胀，引发了某种喂养狂潮，周四将 10 年期国债收益率推至 1.25% 以下的五个月低点，然后最终有所缓和。</blockquote></p><p> But analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .</p><p><blockquote>但分析师表示，此举至少在一定程度上也反映了对全球经济增长前景的合理担忧。</blockquote></p><p> That Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&amp;P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .</p><p><blockquote>周四收益率暴跌以及随之而来的增长担忧引发了广泛的股市抛售，标普500和纳斯达克综合指数从历史高点回落，而道琼斯工业平均指数则在盘中低点下跌了 500 多点。周五股市收盘时收窄跌幅，然后走高，三大股指均创下历史新高。</blockquote></p><p> One casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.</p><p><blockquote>一个受害者是股市再通胀交易。小盘股 Russell 2000 指数 RUT (#phrase-company?ref=company%7CRUT;onlineSignificance=passing-mention) 连续第二周下跌 1.1%，而以科技股为主的纳斯达克 100 指数每周上涨 0.4%。价值股表现不佳，罗素1000价值指数下跌0.3%，而罗素1000增长指数上涨1%。</blockquote></p><p> \"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.</p><p><blockquote>“‘再通胀’和‘轮换’交易——与对疫情和通胀上升中快速、广泛的经济复苏的乐观情绪有关——可以说自第一季度末以来就一直处于低迷状态，但显然本周再次遭受打击，”研究公司凯投宏观（Capital Economics）高级市场经济学家奥利弗·琼斯（Oliver Jones）在周五的一份报告中表示。</blockquote></p><p> Sectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.</p><p><blockquote>他指出，能源和金融等行业以及价值等因素从再通胀/轮换叙事中受益最大，但表现不佳。</blockquote></p><p> Jones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.</p><p><blockquote>琼斯认为，随着供应限制削弱经济活动，对美国经济复苏的乐观情绪达到顶峰是有道理的。全球增长预期也可能面临压力，中国经济可能继续令人失望。</blockquote></p><p> At the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.</p><p><blockquote>与此同时，从绝对值来看，美国经济仍有望实现非常强劲的复苏，远远超过2008年全球金融危机后的复苏。他认为，美国的核心通胀可能会比预期更加持久。</blockquote></p><p> That sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.</p><p><blockquote>他表示，这为“轮换/再通胀贸易标签在未来几个季度可能会逐渐变得不那么有用”的情况埋下了伏笔。</blockquote></p><p> In particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.</p><p><blockquote>他表示，特别是部分贸易，包括大多数股市的快速上涨和能源公司的优异表现，目前可能已经结束，而考虑到美国的增长和通胀路径，国债收益率的下降可能是一种“过度反应”。</blockquote></p><p> Investors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.</p><p><blockquote>未来一周，投资者将看到通胀和增长方面的证据。6 月份消费者价格指数将于周二发布，而生产者价格指数将于周三发布。本周将公布大量其他经济数据，包括周五公布的 6 月份零售销售数据。</blockquote></p><p></p><p> And then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.</p><p><blockquote>然后是企业财报季的开始，随着第二季度利润与去年大流行初期相比猛增，预计该季度将迎来另一个高峰。</blockquote></p><p> \"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.</p><p><blockquote>LPL Financial 首席市场策略师瑞安·德特里克 (Ryan Detrick) 在周五创纪录的收盘后表示：“随着下周财报季开始，门槛设定得相当高，美国企业界最好再创佳绩，否则可能会出现一些令人失望的多头。”</blockquote></p><p> Goodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.</p><p><blockquote>古德温表示，投资者的选择可以归结为要么倾向于有利于周期性股票和短期资产的旧说法，要么倾向于新的说法，即预计经济增长将变得更加缓慢和乏力，就像大流行之前一样，有利于成长型股票和防御性行业。</blockquote></p><p> The best response, however, may be a little bit of both, Goodwin said.</p><p><blockquote>然而，古德温说，最好的反应可能是两者兼而有之。</blockquote></p><p> Reflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.</p><p><blockquote>短期内通货膨胀可能仍有一定的运行空间。她说，儿童税收抵免付款的发放将于本月晚些时候开始，而随着儿童重返校园和额外失业救济金到期，劳动力短缺可能会在未来几个月得到缓解，而消费者正在节省大量资金。</blockquote></p><p> At the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.</p><p><blockquote>她表示，与此同时，经济增长和通胀正在见顶，各种资产类别的估值也捉襟见肘。她表示，虽然仍保持周期性倾斜，但不断变化的背景为投资组合采取更加平衡的方法提供了评级。</blockquote></p><p> Investors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.</p><p><blockquote>她表示，投资者需要密切关注能够利用变化趋势并将价格上涨转嫁给消费者的行业和个别公司，在一个更具选择性的环境中，而不是一个水涨船高的环境。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美国股市经历了疯狂的一周，市场叙事发生了变化——投资者应该相信吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA crazy week for U.S. stocks came with a change in the market narrative -- should investors believe it?<blockquote>美国股市经历了疯狂的一周，市场叙事发生了变化——投资者应该相信吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-07-10 10:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge</p><p><blockquote>投资者必须决定他们是否认为经济增长停滞比通胀飙升构成更大的威胁</blockquote></p><p> <img src=\"https://static.tigerbbs.com/32ec205cf1616aaba5573cc40240a899\" tg-width=\"1260\" tg-height=\"876\"></p><p><blockquote></blockquote></p><p> Fears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right <a href=\"https://laohu8.com/S/AONE.U\">one</a> ?</p><p><blockquote>对通胀失控的担忧已经被对全球经济增长迅速放缓的担忧所取代——这使得美国投资者度过了非常漫长、假期缩短的一周——但这种新的说法正确吗<a href=\"https://laohu8.com/S/AONE.U\">一</a>?</blockquote></p><p> A Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.</p><p><blockquote>国债反弹变成了购买狂潮，导致长期收益率大幅下降。这使得所谓的通货膨胀贸易失去了任何剩余的风力，而通货膨胀贸易有利于对周期性更为敏感的公司的股票，这些公司预计将从价格上涨和经济增长加速中受益最多。</blockquote></p><p> What changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.</p><p><blockquote>有什么变化？纽约人寿投资公司 (New York Life Investments) 的经济学家兼投资组合策略师劳伦·古德温 (Lauren Goodwin) 表示，市场叙事的转变有三个重要因素，该公司管理着 6050 亿美元的资产。</blockquote></p><p> The first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.</p><p><blockquote>她表示，首先是美联储对数据的反应方式发生了明显的变化，投资者不再希望政策制定者像之前认为的那样容忍经济过热和通胀上升。第二，虽然经济增长预计将保持强劲，但增长速度预计将达到峰值。第三，有人担心导致新冠肺炎的三角洲和其他冠状病毒变种的传播可能会迫使新一轮限制，这将给全球经济活动带来压力。</blockquote></p><p> \"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"</p><p><blockquote>古德温在接受电话采访时表示：“总的来说，这与几周前的市场共识叙事截然不同，当时的焦点都是刺激和过热。”他指出，投资者现在必须问：“这种新叙事是正确的吗？”</blockquote></p><p> The real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.</p><p><blockquote>过去一周真正的痛苦在于国债市场，该市场的反弹导致长期收益率大幅下降，价格上涨。此次上涨在很大程度上归因于美国国债空头被迫做空，他们担心通胀，引发了某种喂养狂潮，周四将 10 年期国债收益率推至 1.25% 以下的五个月低点，然后最终有所缓和。</blockquote></p><p> But analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .</p><p><blockquote>但分析师表示，此举至少在一定程度上也反映了对全球经济增长前景的合理担忧。</blockquote></p><p> That Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&amp;P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .</p><p><blockquote>周四收益率暴跌以及随之而来的增长担忧引发了广泛的股市抛售，标普500和纳斯达克综合指数从历史高点回落，而道琼斯工业平均指数则在盘中低点下跌了 500 多点。周五股市收盘时收窄跌幅，然后走高，三大股指均创下历史新高。</blockquote></p><p> One casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.</p><p><blockquote>一个受害者是股市再通胀交易。小盘股 Russell 2000 指数 RUT (#phrase-company?ref=company%7CRUT;onlineSignificance=passing-mention) 连续第二周下跌 1.1%，而以科技股为主的纳斯达克 100 指数每周上涨 0.4%。价值股表现不佳，罗素1000价值指数下跌0.3%，而罗素1000增长指数上涨1%。</blockquote></p><p> \"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.</p><p><blockquote>“‘再通胀’和‘轮换’交易——与对疫情和通胀上升中快速、广泛的经济复苏的乐观情绪有关——可以说自第一季度末以来就一直处于低迷状态，但显然本周再次遭受打击，”研究公司凯投宏观（Capital Economics）高级市场经济学家奥利弗·琼斯（Oliver Jones）在周五的一份报告中表示。</blockquote></p><p> Sectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.</p><p><blockquote>他指出，能源和金融等行业以及价值等因素从再通胀/轮换叙事中受益最大，但表现不佳。</blockquote></p><p> Jones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.</p><p><blockquote>琼斯认为，随着供应限制削弱经济活动，对美国经济复苏的乐观情绪达到顶峰是有道理的。全球增长预期也可能面临压力，中国经济可能继续令人失望。</blockquote></p><p> At the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.</p><p><blockquote>与此同时，从绝对值来看，美国经济仍有望实现非常强劲的复苏，远远超过2008年全球金融危机后的复苏。他认为，美国的核心通胀可能会比预期更加持久。</blockquote></p><p> That sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.</p><p><blockquote>他表示，这为“轮换/再通胀贸易标签在未来几个季度可能会逐渐变得不那么有用”的情况埋下了伏笔。</blockquote></p><p> In particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.</p><p><blockquote>他表示，特别是部分贸易，包括大多数股市的快速上涨和能源公司的优异表现，目前可能已经结束，而考虑到美国的增长和通胀路径，国债收益率的下降可能是一种“过度反应”。</blockquote></p><p> Investors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.</p><p><blockquote>未来一周，投资者将看到通胀和增长方面的证据。6 月份消费者价格指数将于周二发布，而生产者价格指数将于周三发布。本周将公布大量其他经济数据，包括周五公布的 6 月份零售销售数据。</blockquote></p><p></p><p> And then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.</p><p><blockquote>然后是企业财报季的开始，随着第二季度利润与去年大流行初期相比猛增，预计该季度将迎来另一个高峰。</blockquote></p><p> \"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.</p><p><blockquote>LPL Financial 首席市场策略师瑞安·德特里克 (Ryan Detrick) 在周五创纪录的收盘后表示：“随着下周财报季开始，门槛设定得相当高，美国企业界最好再创佳绩，否则可能会出现一些令人失望的多头。”</blockquote></p><p> Goodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.</p><p><blockquote>古德温表示，投资者的选择可以归结为要么倾向于有利于周期性股票和短期资产的旧说法，要么倾向于新的说法，即预计经济增长将变得更加缓慢和乏力，就像大流行之前一样，有利于成长型股票和防御性行业。</blockquote></p><p> The best response, however, may be a little bit of both, Goodwin said.</p><p><blockquote>然而，古德温说，最好的反应可能是两者兼而有之。</blockquote></p><p> Reflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.</p><p><blockquote>短期内通货膨胀可能仍有一定的运行空间。她说，儿童税收抵免付款的发放将于本月晚些时候开始，而随着儿童重返校园和额外失业救济金到期，劳动力短缺可能会在未来几个月得到缓解，而消费者正在节省大量资金。</blockquote></p><p> At the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.</p><p><blockquote>她表示，与此同时，经济增长和通胀正在见顶，各种资产类别的估值也捉襟见肘。她表示，虽然仍保持周期性倾斜，但不断变化的背景为投资组合采取更加平衡的方法提供了评级。</blockquote></p><p> Investors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.</p><p><blockquote>她表示，投资者需要密切关注能够利用变化趋势并将价格上涨转嫁给消费者的行业和个别公司，在一个更具选择性的环境中，而不是一个水涨船高的环境。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/a-crazy-week-for-u-s-stocks-came-with-a-change-in-the-market-narrative-should-investors-believe-it-11625865324?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/a-crazy-week-for-u-s-stocks-came-with-a-change-in-the-market-narrative-should-investors-believe-it-11625865324?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150053623","content_text":"Investors must decide whether they believe stalling economic growth is a bigger threat than an inflation surge\n\nFears of runaway inflation have been swapped for worries about a rapid slowdown in global economic growth -- and that made for one very long, holiday-shortened week for U.S. investors -- but is this new narrative the right one ?\nA Treasury debt rally became a buying frenzy , sending long-term yields sharply lower. That took any remaining wind out of the sails of the so-called reflation trade, which had favored shares of more cyclically sensitive companies expected to benefit the most from rising prices and accelerating economic growth.\nWhat changed? There are three important elements to the shift in the market narrative, said Lauren Goodwin, economist and portfolio strategist at New York Life Investments, which has $605 billion in assets under management.\nThe first is a perceived change in the way the Federal Reserve reacts to data, with investors no longer looking for policy makers to be as tolerant of economic overheating and rising inflation as previously thought, she said. The second is that while economic growth is expected to remain strong, the pace of growth is expected to have peaked . Third, there are worries the spread of the delta and other variants of the coronavirus that causes COVID-19 could force a renewed round of restrictions that will weigh on global economic activity.\n\"Together, that's a very different consensus market narrative than we had a few weeks ago, when the focus was all about stimulus and overheating,\" Goodwin said, in a phone interview, noting that investors must now ask: \"Is this new narrative the right one?\"\nThe real pain in the past week was in the Treasury market, where a rally drove long-term yields sharply lower and prices higher. Much of that rally was attributed to forced short covering by Treasury bears, who had feared inflation, creating something of a feeding frenzy, driving the 10-year yield to a five-month low below 1.25% on Thursday before finally relenting.\nBut analysts said the move, at least in part, also reflected legitimate concerns over the global economic growth outlook .\nThat Thursday dive in yields, and accompanying growth fears, triggered a broad stock-market selloff that saw the S&P 500 and Nasdaq Composite retreat from all-time highs, while the Dow Jones Industrial Average shed more than 500 points at its session low. Stocks trimmed losses by the close and then pushed higher Friday, with all three major indexes finishing at records .\nOne casualty was the stock market reflation trade. The small-cap Russell 2000 index RUT (#phrase-company?ref=COMPANY%7CRUT;onlineSignificance=passing-mention) fell 1.1% for a second straight week of losses, while the tech-heavy Nasdaq-100 saw a 0.4% weekly rise. Value stocks underperformed, with the Russell 1000 Value Index falling 0.3%, while the Russell 1000 Growth Index rose 1%.\n\"The 'reflation' and 'rotation' trades -- associated with optimism about rapid, broad-based economic recovery from the pandemic and higher inflation -- has arguably been flagging since as long ago as the end of the first quarter, but clearly took another hit this week,\" said Oliver Jones, senior markets economist at research firm Capital Economics, in a Friday note.\nSectors, like energy and financials, and factors, such as value, that benefited most from the reflation/rotation narrative have underperformed, he noted.\nJones argued that it makes sense for optimism about the U.S. economic recovery to top out as supply constraints bite into activity. And global growth expectations may also see pressure, with China's economy likely to continue to disappoint.\nAt the same time, the U.S. economy remains on track for a very strong recovery in absolute terms, far exceeding the one that followed the global financial crisis of 2008. And core inflation in the U.S. may prove somewhat more persistent than anticipated, he argued.\nThat sets the stage for a scenario in which \"the rotation/reflation trade label may become progressively less useful in the coming quarters,\" he said.\nIn particular, parts of the trade, including rapid gains in most stock markets and outperformance by energy companies is likely over for now, he said, while the drop in Treasury yields is probably an \"overreaction\" given the path of growth and inflation in the U.S.\nInvestors will get a look at evidence on both the inflation and growth front in the coming week. The June consumer-price index is set for release Tuesday, while a producer-price reading is set for Wednesday. A raft of other economic data is due over the course of the week, including June retail sales figures on Friday.\nAnd then there's the start of the corporate earnings reporting season, which is expected to offer another peak as profits roared in the second quarter relative to the early days of the pandemic last year.\n\"With earnings season kicking off next week, the bar is set quite high and corporate America better produce another stellar quarter or there could be some disappointed bulls,\" said Ryan Detrick, chief market strategist at LPL Financial, after Friday's record close.\nGoodwin said the choice for investors boils down to either leaning into the old narrative that benefits cyclical stocks and shorter duration assets or the new one that expects economic growth to prove more sluggish and anemic, much as it was before the pandemic, favoring growth stocks and defensive sectors.\nThe best response, however, may be a little bit of both, Goodwin said.\nReflation likely still has some room to run in the near term. Distribution of child tax credit payments will begin later this month, while labor shortages may be alleviated in coming months as children return to school and additional unemployment benefits expire, she said, while consumers are sitting on sizable savings.\nAt the same time, growth and inflation are peaking, she said, and valuations are stretched across asset classes. While still maintaining a cyclical tilt, the changing backdrop calls for a more balanced approach to portfolios, she said.\nInvestors need to look closely at sectors and individual companies that can leverage changing trends and pass rising prices on to consumers, she said, in a more selective environment rather than one in which a rising tide raises all boats.","news_type":1,"symbols_score_info":{".IXIC":0.9,".DJI":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":693712913,"gmtCreate":1640078865625,"gmtModify":1640078865830,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"thx","listText":"thx","text":"thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/693712913","repostId":"1149530831","repostType":4,"repost":{"id":"1149530831","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640078220,"share":"https://www.laohunote.com/m/news/1149530831?lang=zh_CN&edition=full","pubTime":"2021-12-21 17:17","market":"us","language":"en","title":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149530831","media":"Tiger Newspress","summary":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Ma","content":"<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会 (EC) 已批准 Veklury 有条件营销授权的变更®（瑞德西韦）包括不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）的科学委员会人用药品委员会（CHMP）于12月16日提出扩大Veklury适应症的积极建议之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着 COVID-19 的发病率再次攀升以及奥密克戎等新变种的出现，我们需要像 Veklury 这样的有效工具来治疗该疾病的各个阶段，”IrsiCaixa 艾滋病研究所 Hospital Universitari Germans Trias I Pujol Badalona，西班牙。“我们现在可以使用 Veklury 来帮助防止高危患者发展为更严重的疾病，即使他们不需要氧气，并继续使用 Veklury 作为治疗严重疾病的关键工具。这项最新的批准也将有助于缓解医疗保健系统的一些压力，这些系统已经因 COVID-19 的负担而承受着巨大的压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>欧盟委员会的决定得到了一项 3 期随机、双盲、安慰剂对照试验结果的支持，该试验评估了在疾病进展高风险的非住院患者中静脉注射 (IV) 三天 Veklury 治疗 COVID-19 的疗效和安全性。在对以1:1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，Veklury显示，与安慰剂（5.3%【15/283】）相比，第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗紧急不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症补充了之前Veklury的有条件营销授权，使其能够治疗患有肺炎的成人和青少年（12至18岁以下，体重至少40 kg）的新冠肺炎，这些肺炎需要补充氧气（低流量或高流量氧气或治疗开始时的其他非侵入性通气）。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官 Merdad Parsey 医学博士表示：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些治疗方法可以在疾病过程的早期使用，以帮助整个欧洲的 COVID-19 患者。”“随着我们对 COVID-19 疾病如何进展的了解越来越多，很明显，如果在疾病过程的早期使用，像 Veklury 这样的抗病毒药物可以产生重大影响。作为 COVID-19 住院患者的抗病毒护理标准，我们为 Veklury 继续在大流行前线发挥的作用感到自豪，我们相信 Veklury 现在将能够帮助欧洲更多患者缩短从 COVID-19 中康复的时间。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.<blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Gilead&nbsp;gained&nbsp;in&nbsp;premarket&nbsp;trading&nbsp;as&nbsp;European Commission&nbsp;approved a variation to the Conditional Marketing Authorization for Veklury.<img src=\"https://static.tigerbbs.com/8d011c5296c3de91e509be97faad6190\" tg-width=\"709\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.</p><p><blockquote>随着欧盟委员会批准了 Veklury 有条件营销授权的变更，吉利德在盘前交易中上涨。吉利德科学公司今天宣布，欧盟委员会 (EC) 已批准 Veklury 有条件营销授权的变更®（瑞德西韦）包括不需要补充氧气且进展为严重新冠肺炎风险增加的成年人。这一决定是在欧洲药品管理局（EMA）的科学委员会人用药品委员会（CHMP）于12月16日提出扩大Veklury适应症的积极建议之后做出的。</blockquote></p><p> \"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"</p><p><blockquote>“随着 COVID-19 的发病率再次攀升以及奥密克戎等新变种的出现，我们需要像 Veklury 这样的有效工具来治疗该疾病的各个阶段，”IrsiCaixa 艾滋病研究所 Hospital Universitari Germans Trias I Pujol Badalona，西班牙。“我们现在可以使用 Veklury 来帮助防止高危患者发展为更严重的疾病，即使他们不需要氧气，并继续使用 Veklury 作为治疗严重疾病的关键工具。这项最新的批准也将有助于缓解医疗保健系统的一些压力，这些系统已经因 COVID-19 的负担而承受着巨大的压力。”</blockquote></p><p> The EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.</p><p><blockquote>欧盟委员会的决定得到了一项 3 期随机、双盲、安慰剂对照试验结果的支持，该试验评估了在疾病进展高风险的非住院患者中静脉注射 (IV) 三天 Veklury 治疗 COVID-19 的疗效和安全性。在对以1:1比例随机分配接受Veklury或安慰剂的562名参与者的分析中，Veklury显示，与安慰剂（5.3%【15/283】）相比，第28天新冠肺炎相关住院或全因死亡的复合主要终点风险降低了87%（0.7%【2/279】），p=0.008。在研究中，到第28天，两组均未观察到死亡。在本试验中，Veklury和安慰剂在各种门诊环境中的安全性特征相似，服用Veklury的患者中最常见的治疗紧急不良事件（≥5%）是恶心和头痛。这些数据还与世界各地的其他监管机构共享，并提交科学同行评审出版物。</blockquote></p><p> This expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).</p><p><blockquote>欧盟的这一扩大适应症补充了之前Veklury的有条件营销授权，使其能够治疗患有肺炎的成人和青少年（12至18岁以下，体重至少40 kg）的新冠肺炎，这些肺炎需要补充氧气（低流量或高流量氧气或治疗开始时的其他非侵入性通气）。</blockquote></p><p> \"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"</p><p><blockquote>吉利德科学首席医疗官 Merdad Parsey 医学博士表示：“欧盟委员会的迅速行动证明了需要有效的治疗方法，这些治疗方法可以在疾病过程的早期使用，以帮助整个欧洲的 COVID-19 患者。”“随着我们对 COVID-19 疾病如何进展的了解越来越多，很明显，如果在疾病过程的早期使用，像 Veklury 这样的抗病毒药物可以产生重大影响。作为 COVID-19 住院患者的抗病毒护理标准，我们为 Veklury 继续在大流行前线发挥的作用感到自豪，我们相信 Veklury 现在将能够帮助欧洲更多患者缩短从 COVID-19 中康复的时间。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149530831","content_text":"Gilead gained in premarket trading as European Commission approved a variation to the Conditional Marketing Authorization for Veklury.Gilead Sciences, Inc. today announced that the European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Veklury® (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the positive recommendation of the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), to expand the indication for Veklury on December 16.\n\"As the rates of COVID-19 climb again and new variants like Omicron emerge, we need effective tools like Veklury to treat various stages of the disease,\" said Roger Paredes, MD, PhD, Chief Infectious Diseases Department, and IrsiCaixa AIDS Research Institute Hospital Universitari Germans Trias I Pujol Badalona, Spain. \"We can now use Veklury to help prevent high-risk patients from progressing to more severe disease, even when they do not require oxygen, as well as continue to utilize Veklury as a key tool in the treatment of severe disease. This latest approval will also help to relieve some of the pressure on healthcare systems that are already under significant strain from the burden of COVID-19.\"\nThe EC’s decision is supported by results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (≥5%) in patients taking Veklury being nausea and headache. These data have also been shared with other regulatory agencies around the world and submitted for scientific peer-reviewed publication.\nThis expanded indication in the EU adds to the previous Conditional Marketing Authorization of Veklury enabling the treatment of COVID-19 in adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).\n\"The swift action of the European Commission is a testament to the need for effective treatments that can be used earlier in the course of disease to help people with COVID-19 across Europe,\" said Merdad Parsey, M.D., Ph.D., Chief Medical Officer, Gilead Sciences. \"As we learn more about how COVID-19 disease progresses, it is clear that an antiviral like Veklury can have a significant impact if used early in the course of disease. As the antiviral standard of care for patients hospitalized with COVID-19, we are proud of the role Veklury continues to play on the front lines of the pandemic, and we believe Veklury will now be able to help more patients decrease their time to recovery from COVID-19 in Europe.\"","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":2946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846181020,"gmtCreate":1636067995588,"gmtModify":1636067996114,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846181020","repostId":"1128227989","repostType":4,"repost":{"id":"1128227989","kind":"news","pubTimestamp":1636067303,"share":"https://www.laohunote.com/m/news/1128227989?lang=zh_CN&edition=full","pubTime":"2021-11-05 07:08","market":"us","language":"en","title":"S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128227989","media":"Reuters","summary":" - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.Financials dropped 1","content":"<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>(路透社）--标普500和纳斯达克周四上涨，将连续六个交易日的历史新高收盘纪录延长，原因是高通（Qualcomm）强劲的财务预测以及投资者消化了美联储开始减少每月债券购买量的决定后，芯片制造商股价大涨。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了连续四点收盘的纪录。摩根大通和高盛集团银行股的下跌给蓝筹股指数带来压力。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>由于美国国债收益率下降，金融股下跌 1.3%，其中大部分是标普500板块，在美联储表示不急于加息的第二天，市场放松了对美联储加快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>“约翰-汉考克投资管理公司（John Hancock Investment Management）联席首席投资策略师马修-米斯金（Matthew Miskin）说：”今天，市场的增长端看到了更多积极的结果，因为它们受益于收益率的下降。</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减收益率，市场总体上一直在为更高的收益率做好准备。当我们今天走进去时，这种情况发生了逆转”。</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌 33.35 点，或 0.09%，至 36,124.23 点；标普500指数上涨 19.49 点，或 0.42%，至 4,680.06 点；纳斯达克综合指数上涨 128.72 点，或 0.81%，至 15,940.31 点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>在标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨 12.7%，该公司预测本季度利润和收入将好于预期，原因是手机、汽车和其他互联网连接设备中使用的芯片需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城东南半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度盈利有助于提振股市情绪。据 Refinitiv IBES 称，由于约有 420 家公司提交了报告，标普500第三季度盈利预计将比去年同期增长 41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>“爱德华-琼斯（Edward Jones）投资策略师克雷格-费尔（Craig Fehr）说：”企业盈利情况仍然相当光明。</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些未能达到本季度预期的公司，更重要的是，也许是预示着前景更加黯淡的公司。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna 股价暴跌约 18%，该公司将 2021 年 COVID-19 疫苗的销售预测削减了多达 50 亿美元，努力填充小瓶并进行分销，以满足前所未有的全球需求。Moderna 股价拖累标普500医疗保健板块，该板块下跌 0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在重获动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌发行量与上涨发行量的比例为 1.12 比 1；在纳斯达克，1.24 比 1 的比率有利于下跌者。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下 75 个 52 周新高和 5 个新低；纳斯达克综合指数创下224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有 113 亿股股票易手，高于过去 20 个交易日的日均 104 亿股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Nasdaq extend record streaks, with boost from chip, growth shares<blockquote>在芯片和成长型股票的推动下，标普500和纳斯达克延续创纪录的连胜纪录</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-05 07:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Reuters) - The S&amp;P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.</p><p><blockquote>(路透社）--标普500和纳斯达克周四上涨，将连续六个交易日的历史新高收盘纪录延长，原因是高通（Qualcomm）强劲的财务预测以及投资者消化了美联储开始减少每月债券购买量的决定后，芯片制造商股价大涨。</blockquote></p><p> The Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase &amp; Co and Goldman Sachs Group weighed on the blue-chip index.</p><p><blockquote>道琼斯工业平均指数小幅下跌，结束了连续四点收盘的纪录。摩根大通和高盛集团银行股的下跌给蓝筹股指数带来压力。</blockquote></p><p> Financials dropped 1.3%, most among S&amp;P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.</p><p><blockquote>由于美国国债收益率下降，金融股下跌 1.3%，其中大部分是标普500板块，在美联储表示不急于加息的第二天，市场放松了对美联储加快加息的预期。</blockquote></p><p> “The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.</p><p><blockquote>“约翰-汉考克投资管理公司（John Hancock Investment Management）联席首席投资策略师马修-米斯金（Matthew Miskin）说：”今天，市场的增长端看到了更多积极的结果，因为它们受益于收益率的下降。</blockquote></p><p> “The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”</p><p><blockquote>“鉴于美联储宣布缩减收益率，市场总体上一直在为更高的收益率做好准备。当我们今天走进去时，这种情况发生了逆转”。</blockquote></p><p> The Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&amp;P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.</p><p><blockquote>道琼斯工业平均指数下跌 33.35 点，或 0.09%，至 36,124.23 点；标普500指数上涨 19.49 点，或 0.42%，至 4,680.06 点；纳斯达克综合指数上涨 128.72 点，或 0.81%，至 15,940.31 点。</blockquote></p><p> The S&amp;P 500 growth index rose 1.2% while the S&amp;P 500 value index fell 0.5%.</p><p><blockquote>标普500增长指数上涨1.2%，标普500价值指数下跌0.5%。</blockquote></p><p> Among S&amp;P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.</p><p><blockquote>在标普500板块中，科技和非必需消费品领涨，均上涨约1.5%。</blockquote></p><p> Qualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.</p><p><blockquote>高通股价上涨 12.7%，该公司预测本季度利润和收入将好于预期，原因是手机、汽车和其他互联网连接设备中使用的芯片需求飙升。</blockquote></p><p> The Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.</p><p><blockquote>费城东南半导体指数上涨3.5%，英伟达飙升12%。</blockquote></p><p> Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&amp;P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.</p><p><blockquote>好于预期的第三季度盈利有助于提振股市情绪。据 Refinitiv IBES 称，由于约有 420 家公司提交了报告，标普500第三季度盈利预计将比去年同期增长 41.2%。</blockquote></p><p> “The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.</p><p><blockquote>“爱德华-琼斯（Edward Jones）投资策略师克雷格-费尔（Craig Fehr）说：”企业盈利情况仍然相当光明。</blockquote></p><p> “The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”</p><p><blockquote>“市场正在奖励那些超出预期并上调前景的公司，而市场正在惩罚那些未能达到本季度预期的公司，更重要的是，也许是预示着前景更加黯淡的公司。”</blockquote></p><p> Moderna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&amp;P 500 healthcare sector, which fell 0.8%.</p><p><blockquote>Moderna 股价暴跌约 18%，该公司将 2021 年 COVID-19 疫苗的销售预测削减了多达 50 亿美元，努力填充小瓶并进行分销，以满足前所未有的全球需求。Moderna 股价拖累标普500医疗保健板块，该板块下跌 0.8%。</blockquote></p><p> Data showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.</p><p><blockquote>数据显示，上周美国新申请失业救济人数降至近20个月来的最低水平，表明经济正在重获动力。投资者将从周五的月度就业报告中获得对经济的批判性看法。</blockquote></p><p> Declining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.</p><p><blockquote>纽约证券交易所下跌发行量与上涨发行量的比例为 1.12 比 1；在纳斯达克，1.24 比 1 的比率有利于下跌者。</blockquote></p><p> The S&amp;P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.</p><p><blockquote>标普500创下 75 个 52 周新高和 5 个新低；纳斯达克综合指数创下224个新高和38个新低。</blockquote></p><p> About 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.</p><p><blockquote>美国交易所约有 113 亿股股票易手，高于过去 20 个交易日的日均 104 亿股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF博时","IVV":"标普500ETF-iShares","OEX":"标普100",".SPX":"S&P 500 Index","SH":"做空标普500-Proshares","SSO":"2倍做多标普500ETF-ProShares","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500 ETF-ProShares",".DJI":"道琼斯","UPRO":"三倍做多标普500ETF-ProShares","SPXU":"三倍做空标普500ETF-ProShares",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-nasdaq-extend-record-streaks-with-boost-from-chip-growth-shares-idUSL1N2RV2T0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128227989","content_text":"(Reuters) - The S&P 500 and Nasdaq rose on Thursday, extending their streaks of record high closes to six sessions, as chipmaker stocks surged following Qualcomm’s strong financial forecast and investors digested the Federal Reserve’s decision to start reducing its monthly bond purchases.\nThe Dow Jones Industrial Average posted a slim loss, ending its streak of record closes at four. Declines in shares of banks JPMorgan Chase & Co and Goldman Sachs Group weighed on the blue-chip index.\nFinancials dropped 1.3%, most among S&P 500 sectors, as U.S. Treasury yields fell, with the market unwinding expectations of quicker Fed rate hikes a day after the central bank signaled it was in no hurry to do so.\n“The growth side of the market is seeing more positive results today as they are benefiting from the falling yields that are developing,” said Matthew Miskin, co-chief investment strategist at John Hancock Investment Management.\n“The market had been positioning for higher yields in general given the Fed announcement of tapering. As we walked in today, there has been a reversal in that.”\nThe Dow Jones Industrial Average fell 33.35 points, or 0.09%, to 36,124.23, the S&P 500 gained 19.49 points, or 0.42%, to 4,680.06 and the Nasdaq Composite added 128.72 points, or 0.81%, to 15,940.31.\nThe S&P 500 growth index rose 1.2% while the S&P 500 value index fell 0.5%.\nAmong S&P 500 sectors, tech and consumer discretionary led the way, both rising about 1.5%.\nQualcomm shares jumped 12.7% as the company forecast better-than-expected profits and revenue for its current quarter on soaring demand for chips used in phones, cars and other internet-connected devices.\nThe Philadelphia SE Semiconductor index climbed 3.5%, with Nvidia soaring 12%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 420 companies having reported, S&P 500 earnings are expected to have climbed 41.2% in the third quarter from a year earlier, according to Refinitiv IBES.\n“The corporate earnings story remains quite bright,” said Craig Fehr, investment strategist at Edward Jones.\n“The market is rewarding companies that are beating and upping their outlook, and the market is punishing companies that are missing their estimates in the quarter and more importantly, perhaps, signaling a more sour outlook.”\nModerna shares tumbled about 18% as the company slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand. Moderna shares weighed on the S&P 500 healthcare sector, which fell 0.8%.\nData showed the number of Americans filing new claims for unemployment benefits fell to the lowest level in nearly 20 months last week, suggesting the economy was regaining momentum. Investors will get a critical view of the economy with the monthly jobs report on Friday.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.\nThe S&P 500 posted 75 new 52-week highs and five new lows; the Nasdaq Composite recorded 224 new highs and 38 new lows.\nAbout 11.3 billion shares changed hands in U.S. exchanges, above the 10.4 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,".SPX":0.9,"ESmain":0.9,".IXIC":0.9,".DJI":0.9,"OEX":0.9,"SPXU":0.9,"UPRO":0.9,"SH":0.9,"SSO":0.9,"OEF":0.9,"IVV":0.9,"SDS":0.9}},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822013471,"gmtCreate":1634078431219,"gmtModify":1634078431459,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/822013471","repostId":"1198930462","repostType":4,"repost":{"id":"1198930462","kind":"news","pubTimestamp":1634044920,"share":"https://www.laohunote.com/m/news/1198930462?lang=zh_CN&edition=full","pubTime":"2021-10-12 21:22","market":"us","language":"en","title":"Why you won’t know it when a bear market starts<blockquote>为什么熊市开始时你不会知道</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198930462","media":"MarketWatch","summary":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n","content":"<p>It’s crucial to devise a strategy that you can live with through a bear market</p><p><blockquote>制定一个能够度过熊市的策略至关重要</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/82a6b41119b11a31337948b9b003acab\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>AFP via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>法新社盖蒂图片社</span></p></blockquote></p><p> It was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.</p><p><blockquote>14年前的本周，即2007年10月9日，股市在金融危机引发的熊市开始之前触及牛市高点。</blockquote></p><p> I am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&amp;P 500&nbsp;was 120% higher than where it had stood at the beginning of that bull market, five years previously.</p><p><blockquote>我敢打赌，那天你脑子里最后一件事就是新的熊市是否开始了。相反，您无疑正在分享伴随着又一个牛市新高的繁荣。标普500比五年前牛市开始时的水平高出 120%。</blockquote></p><p> And, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&amp;P 500 over the subsequent 16 months would <i>lose</i> 55%.</p><p><blockquote>然而，美国历史上最严重的熊市之一就在那一天开始了。随后16个月的标普500将<i>失去</i>55%.</blockquote></p><p> This walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.</p><p><blockquote>这条记忆之路非常重要，因为它提醒我们，牛市顶部并不能被实时识别。直到事实证明，牛市已经结束。</blockquote></p><p> Many clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.</p><p><blockquote>许多客户强烈不同意我的观点，坚称他们事实上确实很清楚牛市在 2007 年 10 月达到顶峰。但他们几乎可以肯定是在改写历史，这是可以理解的。改写过去是人之常情，让事情看起来会像以前那样发展。</blockquote></p><p> But the beginning of the 2007-2009 bear market was anything but obvious in the moment.</p><p><blockquote>但2007-2009年熊市的开始在当时一点也不明显。</blockquote></p><p> If you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.</p><p><blockquote>如果您有任何疑问，请考虑我公司每天监控的近 100 个短期股票市场计时器子集中的平均推荐股票敞口。(平均而言，HSNSI 指数在牛市见顶的当天达到最高水平。</blockquote></p><p> This is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.</p><p><blockquote>这在随附的图表中说明。它平均了过去 40 年每次牛市顶部之前和之后六周的 HSNSI（根据 Ned Davis Research 维护的日历）。如您所见，HSNSI 在平均牛市的最后六周上涨了 20 个百分点，然后在随后的熊市的前六周下跌了 40 个百分点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8bc18ef162a6e98217aada4619d99651\" tg-width=\"700\" tg-height=\"488\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?</p><p><blockquote>换句话说，专业市场计时器平均在他们应该最悲观的日子里最乐观。他们是整天、每天跟踪市场的专业人士。如果他们不能做得更好，那你凭什么认为你可以？</blockquote></p><p> <b>Comments of market timers</b></p><p><blockquote><b>市场计时器的评论</b></blockquote></p><p> I think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:</p><p><blockquote>我认为这些统计数据令人信服。但为了锦上添花，请考虑时事通讯编辑在 2007 年 10 月市场顶部当天或之前几天发表的具有代表性的评论样本：</blockquote></p><p> <ul>  <li>“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”</li>  <li>“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”</li>  <li>“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”</li>  <li>“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]</li>  <li>“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”</li>  <li>“The longer-term bull market is intact… You should be looking to buy on any weakness.”</li> </ul> Their exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.</p><p><blockquote><ul><li>“仔细一听，就能听到隆隆声，那隆隆声是这次大牛市第三阶段的遥远雷声……我看到好时光滚滚而来，我真的看到了。”</li><li>“我已经有一段时间没有对用我们的大钱获得巨额利润的潜力充满信心了。因此，如果你还没有这样做，那么你必须尽快把钱投入到这个[股票]市场中。时间不等人，你的钱也在等着你。那就去做吧。”</li><li>“全球股市的牛市不仅在继续，而且.还在进入一个强劲的阶段.现在美联储已经挥舞着降息的旗帜，真的没有什么能阻挡市场了。”</li><li>“道琼斯指数 16,000 点来了.在我们看来，未来 3 到 6 个月股市将进入竞争状态。”[2007 年 10 月牛市顶部当天道琼斯指数为 14,165 点。]</li><li>“熊市周期性跌幅超过 20% 的风险并未出现在雷达屏幕上。”</li><li>“长期牛市是完好无损的.你应该在任何疲软的时候买入”。</li></ul>他们的热情是显而易见的，不是吗？不管你今天会给自己讲什么故事，你那天的感受都很有可能是这样。</blockquote></p><p> <b>Investment lesson</b></p><p><blockquote><b>投资教训</b></blockquote></p><p> The investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.</p><p><blockquote>投资含义很明确：不要指望能够减少股票敞口来避开熊市。</blockquote></p><p> This is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&amp;P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.</p><p><blockquote>这就是为什么你应该设计并遵循一个可以度过熊市的策略。如果你在牛市期间100%投资，直到标普500见顶，然后在熊市期间100%持有现金，那么它的收益不一定能达到理论上的最高收益。但是在现实世界中没有人达到理论上的最大值。</blockquote></p><p> The perfect is the enemy of the good, in other words.</p><p><blockquote>换句话说，完美是善的敌人。</blockquote></p><p></p><p> For the record, I have no idea whether a bear market has started. It’s been over a month now since the S&amp;P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.</p><p><blockquote>郑重声明，我不知道熊市是否已经开始。标普500创下迄今为止的牛市高点已经一个多月了，目前的交易价格比该高点低了近 3%。</blockquote></p><p> But if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.</p><p><blockquote>但如果它已经开始，我们要等到几个月后，也就是市场价格大幅下跌的时候才能确定。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why you won’t know it when a bear market starts<blockquote>为什么熊市开始时你不会知道</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy you won’t know it when a bear market starts<blockquote>为什么熊市开始时你不会知道</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-10-12 21:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It’s crucial to devise a strategy that you can live with through a bear market</p><p><blockquote>制定一个能够度过熊市的策略至关重要</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/82a6b41119b11a31337948b9b003acab\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>AFP via Getty Images</span></p><p><blockquote><p class=\"t-img-caption\"><span>法新社盖蒂图片社</span></p></blockquote></p><p> It was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.</p><p><blockquote>14年前的本周，即2007年10月9日，股市在金融危机引发的熊市开始之前触及牛市高点。</blockquote></p><p> I am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&amp;P 500&nbsp;was 120% higher than where it had stood at the beginning of that bull market, five years previously.</p><p><blockquote>我敢打赌，那天你脑子里最后一件事就是新的熊市是否开始了。相反，您无疑正在分享伴随着又一个牛市新高的繁荣。标普500比五年前牛市开始时的水平高出 120%。</blockquote></p><p> And, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&amp;P 500 over the subsequent 16 months would <i>lose</i> 55%.</p><p><blockquote>然而，美国历史上最严重的熊市之一就在那一天开始了。随后16个月的标普500将<i>失去</i>55%.</blockquote></p><p> This walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.</p><p><blockquote>这条记忆之路非常重要，因为它提醒我们，牛市顶部并不能被实时识别。直到事实证明，牛市已经结束。</blockquote></p><p> Many clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.</p><p><blockquote>许多客户强烈不同意我的观点，坚称他们事实上确实很清楚牛市在 2007 年 10 月达到顶峰。但他们几乎可以肯定是在改写历史，这是可以理解的。改写过去是人之常情，让事情看起来会像以前那样发展。</blockquote></p><p> But the beginning of the 2007-2009 bear market was anything but obvious in the moment.</p><p><blockquote>但2007-2009年熊市的开始在当时一点也不明显。</blockquote></p><p> If you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.</p><p><blockquote>如果您有任何疑问，请考虑我公司每天监控的近 100 个短期股票市场计时器子集中的平均推荐股票敞口。(平均而言，HSNSI 指数在牛市见顶的当天达到最高水平。</blockquote></p><p> This is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.</p><p><blockquote>这在随附的图表中说明。它平均了过去 40 年每次牛市顶部之前和之后六周的 HSNSI（根据 Ned Davis Research 维护的日历）。如您所见，HSNSI 在平均牛市的最后六周上涨了 20 个百分点，然后在随后的熊市的前六周下跌了 40 个百分点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8bc18ef162a6e98217aada4619d99651\" tg-width=\"700\" tg-height=\"488\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> In other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?</p><p><blockquote>换句话说，专业市场计时器平均在他们应该最悲观的日子里最乐观。他们是整天、每天跟踪市场的专业人士。如果他们不能做得更好，那你凭什么认为你可以？</blockquote></p><p> <b>Comments of market timers</b></p><p><blockquote><b>市场计时器的评论</b></blockquote></p><p> I think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:</p><p><blockquote>我认为这些统计数据令人信服。但为了锦上添花，请考虑时事通讯编辑在 2007 年 10 月市场顶部当天或之前几天发表的具有代表性的评论样本：</blockquote></p><p> <ul>  <li>“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”</li>  <li>“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”</li>  <li>“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”</li>  <li>“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]</li>  <li>“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”</li>  <li>“The longer-term bull market is intact… You should be looking to buy on any weakness.”</li> </ul> Their exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.</p><p><blockquote><ul><li>“仔细一听，就能听到隆隆声，那隆隆声是这次大牛市第三阶段的遥远雷声……我看到好时光滚滚而来，我真的看到了。”</li><li>“我已经有一段时间没有对用我们的大钱获得巨额利润的潜力充满信心了。因此，如果你还没有这样做，那么你必须尽快把钱投入到这个[股票]市场中。时间不等人，你的钱也在等着你。那就去做吧。”</li><li>“全球股市的牛市不仅在继续，而且.还在进入一个强劲的阶段.现在美联储已经挥舞着降息的旗帜，真的没有什么能阻挡市场了。”</li><li>“道琼斯指数 16,000 点来了.在我们看来，未来 3 到 6 个月股市将进入竞争状态。”[2007 年 10 月牛市顶部当天道琼斯指数为 14,165 点。]</li><li>“熊市周期性跌幅超过 20% 的风险并未出现在雷达屏幕上。”</li><li>“长期牛市是完好无损的.你应该在任何疲软的时候买入”。</li></ul>他们的热情是显而易见的，不是吗？不管你今天会给自己讲什么故事，你那天的感受都很有可能是这样。</blockquote></p><p> <b>Investment lesson</b></p><p><blockquote><b>投资教训</b></blockquote></p><p> The investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.</p><p><blockquote>投资含义很明确：不要指望能够减少股票敞口来避开熊市。</blockquote></p><p> This is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&amp;P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.</p><p><blockquote>这就是为什么你应该设计并遵循一个可以度过熊市的策略。如果你在牛市期间100%投资，直到标普500见顶，然后在熊市期间100%持有现金，那么它的收益不一定能达到理论上的最高收益。但是在现实世界中没有人达到理论上的最大值。</blockquote></p><p> The perfect is the enemy of the good, in other words.</p><p><blockquote>换句话说，完美是善的敌人。</blockquote></p><p></p><p> For the record, I have no idea whether a bear market has started. It’s been over a month now since the S&amp;P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.</p><p><blockquote>郑重声明，我不知道熊市是否已经开始。标普500创下迄今为止的牛市高点已经一个多月了，目前的交易价格比该高点低了近 3%。</blockquote></p><p> But if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.</p><p><blockquote>但如果它已经开始，我们要等到几个月后，也就是市场价格大幅下跌的时候才能确定。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/why-you-wont-know-it-when-a-bear-market-starts-11633654477?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198930462","content_text":"It’s crucial to devise a strategy that you can live with through a bear market\nAFP via Getty Images\n\nIt was on Oct. 9, 2007, 14 years ago this week, that the stock market hit its bull market high prior to the beginning of the Financial Crisis-induced bear market.\nI am willing to bet that the last thing on your mind that day was whether a new bear market was beginning. Instead, you undoubtedly were sharing in the exuberance that accompanied yet another new bull-market high. The S&P 500 was 120% higher than where it had stood at the beginning of that bull market, five years previously.\nAnd, yet, one of the worst bear markets in U.S. history was beginning on that very day. The S&P 500 over the subsequent 16 months would lose 55%.\nThis walk down memory lane is important because it serves as a reminder that bull market tops aren’t recognized in real time. It’s only after the fact that it becomes clear that the bull market has ended.\nMany clients strenuously disagree with me about this, insisting that they in fact did have a good sense the bull market was topping out in October 2007. But they almost certainly are rewriting history, which is understandable. It’s human nature to rewrite the past to make it seem obvious that events would unfold as they did.\nBut the beginning of the 2007-2009 bear market was anything but obvious in the moment.\nIf you have any doubt, consider the average recommended equity exposure among a subset of nearly 100 short-term stock market timers my firm monitors on a daily basis. (This average is what’s represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI.) On average, the HSNSI reaches its highest level on the very day the bull market tops out.\nThis is illustrated in the accompanying chart. It averages the HSNSI over the six weeks prior and six weeks subsequent to every bull market top of the last 40 years (per the calendar maintained by Ned Davis Research). As you can see, the HSNSI rises 20 percentage points over the final six weeks of the average bull market, and then plunges 40 percentage points over the first six weeks of the subsequent bear market.\n\n\nIn other words, professional market timers on average are most optimistic on the very day they should be most pessimistic. They are professionals who follow the market all day, every day. If they can’t do better, then what makes you think you can?\nComments of market timers\nI think these statistics make a compelling case. But to add anecdotal icing to the cake, consider a representative sampling of comments made by newsletter editors on the exact day of the October 2007 market top, or in the days immediately prior:\n\n“If you listen carefully, you can hear the rumbling. That rumbling is the distant thunder of the third phase of this great bull market… I see the good times rolling, I really do.”\n“It’s been a while since I’ve felt so confident about the potential for making some great gains with our serious money. So, if you haven’t done so already, it is essential that you get your money into this [stock] market as quickly as possible. Time waits for no man, and your money is waiting on you. So go to it.”\n“The global bull market in stocks not only continues, but… it’s also entering a strong phase… Now that the Fed has waved the flag that interest rates are going lower, there’s really nothing holding the market back.”\n“Dow 16,000 here we come… [I]t appears to us that the stock market is off to the races for the next 3 to 6 months.” [The Dow on the day of the October 2007 bull market top was 14,165.]\n“The risk of a cyclical bear market decline in excess of 20% is not on the radar screen.”\n“The longer-term bull market is intact… You should be looking to buy on any weakness.”\n\nTheir exuberance is palpable, isn’t it? And odds are overwhelming that that’s how you felt too on that day—regardless of what story you may be telling yourself today.\nInvestment lesson\nThe investment implication is clear: Do not count on being able to reduce your equity exposure in order to sidestep a bear market.\nThis is why you should devise and then follow a strategy you can live with through a bear market. It won’t necessarily make as much money as the theoretical maximum you could make if you were to be 100% invested during bull markets up until the exact day of the S&P 500’s top, and then moved to be 100% in cash for the duration of the bear market. But no one achieves that theoretical maximum in the real world.\nThe perfect is the enemy of the good, in other words.\nFor the record, I have no idea whether a bear market has started. It’s been over a month now since the S&P 500 hit what so far has been its bull market high, and it is currently trading nearly 3% lower than that high.\nBut if it has started, we won’t know for sure until many months from now and when the market is a whole lot lower.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":885,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881106606,"gmtCreate":1631313763405,"gmtModify":1632883288299,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881106606","repostId":"2166137557","repostType":4,"isVote":1,"tweetType":1,"viewCount":605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":699829799,"gmtCreate":1639783265714,"gmtModify":1639783265921,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"like pls","listText":"like pls","text":"like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699829799","repostId":"2192497854","repostType":4,"isVote":1,"tweetType":1,"viewCount":2832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609690307,"gmtCreate":1638274281322,"gmtModify":1638274281408,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582888796077977","idStr":"3582888796077977"},"themes":[],"title":"","htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609690307","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohunote.com/m/news/1192203085?lang=zh_CN&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&amp;Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&amp;Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates<blockquote>初步测试表明，新冠肺炎抗体药物受到奥密克戎的挑战</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-11-30 19:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p><p><blockquote>再生元表示，其抗体药物鸡尾酒被发现对新变种失去效力</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p><p><blockquote><p class=\"t-img-caption\"><span>今年早些时候，佛罗里达州彭布罗克派恩斯的一个单克隆抗体治疗点。</span></p></blockquote></p><p> Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p><p><blockquote>再生元制药公司周二表示，初步测试表明，该公司生产的 Covid-19 抗体药物鸡尾酒对奥密克戎病毒失去了效力，这表明如果新菌株广泛传播，一类重要疗法中的一些产品可能需要修改。</blockquote></p><p> Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p><p><blockquote>外部科学家说，对礼来公司（Eli Lilly&amp;Co.礼来公司表示，它正在对这种新变种进行抗体治疗测试，不愿猜测结果会如何。</blockquote></p><p> The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p><p><blockquote>这些发现是研究人员竞赛的早期结果，旨在评估新的奥密克戎变种对病人、医生和医院一直依赖的 Covid-19 治疗方法的影响，以及正在开发的有望让人们远离医院的药丸。</blockquote></p><p> Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p><p><blockquote>研究人员表示，一些抗体疗法可能特别容易受到奥密克戎病毒的影响，因为它包含再生元和礼来公司药物所针对的刺突蛋白的突变，而其他药物应该能很好地保持，因为它们攻击的是病毒变异体中不变的元素。</blockquote></p><p> Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p><p><blockquote>单克隆抗体是实验室制造的分子，来源于新冠肺炎的幸存者或被改造成具有人类免疫系统的小鼠。当在感染后不久服用时，这些药物会附着在冠状病毒表面，并阻止其在新细胞中自我复制。</blockquote></p><p> They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p><p><blockquote>它们是唯一被授权用于治疗需要住院治疗的患者的药物，这些患者有发生严重病例的高风险。</blockquote></p><p> The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p><p><blockquote>这些药物不同于疫苗，疫苗训练免疫系统如何抵御病毒，包括产生抗体。去年，前总统唐纳德-特朗普（Donald Trump）将他从 Covid-19 中快速康复归功于再生元公司的药物。</blockquote></p><p> Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p><p><blockquote>再生元表示，在完成进一步测试后，它将能够在未来几周内量化该变种的影响。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p><p><blockquote><p class=\"t-img-caption\"><span>辉瑞公司的 Paxlovid 等抗病毒药物似乎不受该变种的影响。</span></p></blockquote></p><p> If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p><p><blockquote>Regeneron 总裁兼首席科学官 George Yancopoulos 说，如果最终测试表明其抗体药物对奥密克戎病毒的疗效较差，那么 Regeneron 已经开发出了替代抗体，可以将其推入临床试验，并认为这些抗体将保持对该变异病毒的疗效。</blockquote></p><p> One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p><p><blockquote>再生元公司的一种替代抗体已经在进行临床试验，该公司之所以开始临床试验，是因为预计随着时间的推移会出现新的变种。</blockquote></p><p> The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p><p><blockquote>南非科学家上周发现了奥密克戎变种，这促使药物研究人员争先恐后地看看，如果这种新毒株最终广泛传播，相对较小的新冠肺炎治疗药物箱是否仍然可以对抗它。</blockquote></p><p> “What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p><p><blockquote>“扬科普洛斯博士在接受采访时说：”我们不得不承认，在过去的六天里，我们的紧迫感增加了。“最初的后备计划现在变得更加紧迫”。</blockquote></p><p> Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p><p><blockquote>西雅图弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Center）和西雅图华盛顿大学（University of Washington in Seattle）的博士生艾莉-格里尼（Allie Greaney）说，该中心的科学家发现，奥密克戎病毒的个别突变会降低或消除再生元公司和礼来公司的药物附着在病毒上的能力。</blockquote></p><p> More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p><p><blockquote>她说，需要对这些药物针对整个变种进行更全面的测试，以充分了解其影响。“格里尼女士说：”我不确定这种影响的确切程度，但效果可能会较差。</blockquote></p><p> Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p><p><blockquote>礼来公司病毒学家兼研究顾问妮可·卡勒瓦德 (Nicole Kallewaard) 表示，礼来公司正在测试针对其药物的新变种，该药物是两种抗体的组合，称为 bamlanivimab 和 etesevimab。</blockquote></p><p> She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p><p><blockquote>她拒绝对显示针对单个奥密克戎突变的有效性降低的结果发表评论，因为当所有突变组合时，结果可能会有所不同。</blockquote></p><p> “I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p><p><blockquote>“卡勒瓦德博士说：”我认为我们需要等待整个病毒的确认。“希望数据能在未来几周内公布”。</blockquote></p><p> A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p><p><blockquote>奥密克戎病患病率的上升可能会为竞争对手提供一个机会，他们说自己的药物在初步测试中似乎没有受到这种变异的影响，其中包括 Vir Biotechnology Inc. 和葛兰素史克公司，后者的药物 sotrovimab 已于今年早些时候获准紧急使用。</blockquote></p><p></p><p> Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p><p><blockquote>Fred Hutchinson研究人员还表示，他们的初步测试表明，Vir-GSK抗体药物保留了其有效性。</blockquote></p><p> Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p><p><blockquote>Adagio Therapeutics Inc. 是一家生物技术公司，其 Covid-19 抗体药物正在进行临床试验，该公司表示，其抗体似乎也不受新变种的影响。</blockquote></p><p> Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p><p><blockquote>Vir、Glaxo 和 Adagio 表示，他们正在进行进一步的测试，以确认他们的药物不受奥密克戎病毒的影响。</blockquote></p><p> Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p><p><blockquote>科学家说，奥密克戎病毒对实验室制造的抗体药物以及疫苗产生的抗体构成威胁，因为这种新变种在病毒的刺突蛋白部分发生突变，已知抗体经常附着在刺突蛋白部分。</blockquote></p><p> Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p><p><blockquote>Vir 和 Adagio 的官员表示，这两家公司设计抗体的目的是针对不同冠状病毒中常见的病毒斑点，这些斑点即使经过多年的多次突变也保持稳定。</blockquote></p><p> “They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p><p><blockquote>“Adagio 首席执行官蒂尔曼-格恩格罗斯（Tillman Gerngross）在接受采访时说：”它们与病毒中的一个区域结合在一起，这个区域经过几十年的演变并没有太大变化。“这些保守区域使病毒更容易受到抗体的攻击”。</blockquote></p><p> It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p><p><blockquote>公司官员表示，创建完整的奥密克戎病毒变种版本并测试针对它的抗体药物至少需要两周时间。尽管如此，科学家们表示，他们对这种变异体逃避疫苗、既往感染或药物治疗产生的抗体的能力感到担忧。</blockquote></p><p> “Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p><p><blockquote>“Vir 首席科学官 Skip Virgin 在接受采访时说：”奥密克戎还没有成为下一个三角洲。但 “我们认为，突变的程度和数量意味着世界需要非常认真地对待奥密克戎”。</blockquote></p><p> Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p><p><blockquote>米歇尔·努森茨威格 (Michel Nussenzweig) 表示，正在评估授权的抗病毒药物，包括默克公司 (Merck&amp;Co.) 及其合作伙伴 Ridgeback Biotherapeutics LP 和辉瑞公司 (Pfizer Inc.) 的药丸，似乎不受该变种的影响，因为它们针对的是病毒上的不同位点。洛克菲勒大学免疫学家。</blockquote></p><p> Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p><p><blockquote>医生和患者一直期待着这种药丸的授权，在临床试验中，如果服用得足够早，这种药丸可以降低住院的风险。</blockquote></p><p> “The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p><p><blockquote>“Nussenzweig 博士说：”药丸的目标似乎压力较小，可能没问题，但这也需要进行测试。</blockquote></p><p> Pfizer and Merck said they expect their drugs to be effective against Omicron.</p><p><blockquote>辉瑞和默克表示，他们预计自己的药物能够有效对抗奥密克戎病。</blockquote></p><p> Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p><p><blockquote>吉利德科学公司还表示，预计其用于治疗住院患者的抗病毒药物 Veklury 将保持对奥密克戎病毒的有效性，就像对其他令人担忧的变种一样。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}